NZ613917B2 - 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diazaspiro[5.5]undecan-5-one dimaleate, use thereof as a drug, and production thereof - Google Patents
9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diazaspiro[5.5]undecan-5-one dimaleate, use thereof as a drug, and production thereof Download PDFInfo
- Publication number
- NZ613917B2 NZ613917B2 NZ613917A NZ61391712A NZ613917B2 NZ 613917 B2 NZ613917 B2 NZ 613917B2 NZ 613917 A NZ613917 A NZ 613917A NZ 61391712 A NZ61391712 A NZ 61391712A NZ 613917 B2 NZ613917 B2 NZ 613917B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- formula
- compound
- methoxy
- oxo
- quinazolin
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 7
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- JPFLINXTDIKQQV-SPIKMXEPSA-N (Z)-but-2-enedioic acid;9-[4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxy-1,4-diazaspiro[5.5]undecan-5-one Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C=12C=C(OC3CCC4(CC3)C(NCCN4)=O)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1F JPFLINXTDIKQQV-SPIKMXEPSA-N 0.000 title abstract 2
- 229940079593 drugs Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 153
- 238000000034 method Methods 0.000 claims abstract description 67
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims abstract description 42
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 27
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 20
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims abstract description 16
- VZGDMQKNWNREIO-UHFFFAOYSA-N Carbon tetrachloride Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims abstract description 14
- XHXFXVLFKHQFAL-UHFFFAOYSA-N Phosphoryl chloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims abstract description 14
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 12
- 230000000707 stereoselective Effects 0.000 claims abstract description 12
- ASWXNYNXAOQCCD-UHFFFAOYSA-N dichloro(triphenyl)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(Cl)(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 ASWXNYNXAOQCCD-UHFFFAOYSA-N 0.000 claims abstract description 8
- UHZYTMXLRWXGPK-UHFFFAOYSA-N Phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000005660 chlorination reaction Methods 0.000 claims abstract description 7
- IBDMRHDXAQZJAP-UHFFFAOYSA-N dichlorophosphorylbenzene Chemical compound ClP(Cl)(=O)C1=CC=CC=C1 IBDMRHDXAQZJAP-UHFFFAOYSA-N 0.000 claims abstract description 7
- VKRKCBWIVLSRBJ-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decan-8-one Chemical compound C1CC(=O)CCC21OCCO2 VKRKCBWIVLSRBJ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000010586 diagram Methods 0.000 claims abstract description 6
- 239000000376 reactant Substances 0.000 claims abstract description 4
- -1 orus pentachloride Chemical compound 0.000 claims description 40
- 238000006243 chemical reaction Methods 0.000 claims description 32
- 230000001681 protective Effects 0.000 claims description 14
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 11
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 10
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 10
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Chemical compound [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 claims description 9
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 claims description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 7
- MPBUCOHXXNOLAZ-UHFFFAOYSA-N 3-chloro-N-fluoroaniline Chemical compound FNC1=CC=CC(Cl)=C1 MPBUCOHXXNOLAZ-UHFFFAOYSA-N 0.000 claims description 6
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N Trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- XMAWMRNILPLCMA-UHFFFAOYSA-L N-carboxylatoiminocarbamate;triphenylphosphane Chemical compound [O-]C(=O)N=NC([O-])=O.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 XMAWMRNILPLCMA-UHFFFAOYSA-L 0.000 claims description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 5
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (NE)-N-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 claims description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 5
- FAMRKDQNMBBFBR-BQYQJAHWSA-N Diethyl azodicarboxylate Chemical compound CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 200000000018 inflammatory disease Diseases 0.000 claims description 4
- 229910052808 lithium carbonate Inorganic materials 0.000 claims description 4
- 239000011976 maleic acid Substances 0.000 claims description 4
- 229910052763 palladium Inorganic materials 0.000 claims description 4
- 235000015320 potassium carbonate Nutrition 0.000 claims description 4
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 3
- 239000012448 Lithium borohydride Substances 0.000 claims description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N Sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 3
- TUQOTMZNTHZOKS-UHFFFAOYSA-N Tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 claims description 3
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 3
- 235000017550 sodium carbonate Nutrition 0.000 claims description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N Potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N Sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000005712 crystallization Effects 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims description 2
- SXCQOWSCNMKTFA-UHFFFAOYSA-N phosphorosobenzene Chemical compound O=PC1=CC=CC=C1 SXCQOWSCNMKTFA-UHFFFAOYSA-N 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract description 17
- APKRDOMMNFBDSG-UHFFFAOYSA-M 2-propylnonanoate Chemical compound CCCCCCCC(C([O-])=O)CCC APKRDOMMNFBDSG-UHFFFAOYSA-M 0.000 abstract description 11
- 230000000875 corresponding Effects 0.000 abstract description 4
- 239000000543 intermediate Substances 0.000 abstract 2
- 235000013350 formula milk Nutrition 0.000 description 85
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 64
- 239000000203 mixture Substances 0.000 description 50
- 239000000126 substance Substances 0.000 description 45
- 235000002639 sodium chloride Nutrition 0.000 description 35
- 239000011780 sodium chloride Substances 0.000 description 35
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 150000003839 salts Chemical class 0.000 description 27
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 22
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 21
- 239000000047 product Substances 0.000 description 20
- 239000003826 tablet Substances 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 19
- 239000012453 solvate Substances 0.000 description 19
- 238000007792 addition Methods 0.000 description 17
- 150000004677 hydrates Chemical class 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000002253 acid Substances 0.000 description 16
- 239000002904 solvent Substances 0.000 description 15
- 239000000725 suspension Substances 0.000 description 15
- 235000019441 ethanol Nutrition 0.000 description 14
- 229960004756 ethanol Drugs 0.000 description 14
- 239000002464 receptor antagonist Substances 0.000 description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 14
- 239000002244 precipitate Substances 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 238000001035 drying Methods 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 238000001819 mass spectrum Methods 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000002775 capsule Substances 0.000 description 11
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 11
- 102100006973 CYSLTR1 Human genes 0.000 description 10
- FIMXSEMBHGTNKT-RZVDLVGDSA-N Scopine Chemical compound C([C@@H]1N2C)[C@H](O)C[C@@H]2[C@@H]2[C@H]1O2 FIMXSEMBHGTNKT-RZVDLVGDSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
- HWACEPZXFJTFSW-HTQZYQBOSA-N (1S,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-en-5-ol Chemical compound C1C=C[C@@]2(O)CC[C@@H]1N2C HWACEPZXFJTFSW-HTQZYQBOSA-N 0.000 description 8
- 229920002261 Corn starch Polymers 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 108010002279 leukotriene D4 receptor Proteins 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 206010006451 Bronchitis Diseases 0.000 description 7
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 7
- 229960001375 Lactose Drugs 0.000 description 7
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 7
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 210000004027 cells Anatomy 0.000 description 7
- 239000008120 corn starch Substances 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 7
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 230000001078 anti-cholinergic Effects 0.000 description 6
- 239000003246 corticosteroid Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrugs Drugs 0.000 description 6
- 239000000829 suppository Substances 0.000 description 6
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-Methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 5
- KYWIYKKSMDLRDC-UHFFFAOYSA-N 2-Undecanone Chemical compound CCCCCCCCCC(C)=O KYWIYKKSMDLRDC-UHFFFAOYSA-N 0.000 description 5
- 229940121647 EGFR inhibitors Drugs 0.000 description 5
- 239000001828 Gelatine Substances 0.000 description 5
- 230000000172 allergic Effects 0.000 description 5
- 201000008937 atopic dermatitis Diseases 0.000 description 5
- 150000003842 bromide salts Chemical class 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 229940006211 Anticholinergic mydriatics and cycloplegics Drugs 0.000 description 4
- 229940065524 Anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 4
- 208000006673 Asthma Diseases 0.000 description 4
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 4
- 102000002791 Interleukin-8B Receptors Human genes 0.000 description 4
- 210000004072 Lung Anatomy 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- UAEPNZWRGJTJPN-UHFFFAOYSA-N Methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 4
- 230000000954 anitussive Effects 0.000 description 4
- 230000003042 antagnostic Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 4
- 230000003454 betamimetic Effects 0.000 description 4
- 239000000812 cholinergic antagonist Substances 0.000 description 4
- 229940031098 ethanolamine Drugs 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- 125000005635 hydromethanesulphonate group Chemical group 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 3
- XWBTZHDDWRNOQH-UHFFFAOYSA-N 3-chloro-2-fluoroaniline Chemical compound NC1=CC=CC(Cl)=C1F XWBTZHDDWRNOQH-UHFFFAOYSA-N 0.000 description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
- 102000010183 Bradykinin Receptors Human genes 0.000 description 3
- 108050001736 Bradykinin receptor family Proteins 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butanoic acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- 101700011366 CXCR1 Proteins 0.000 description 3
- 102100014035 CXCR1 Human genes 0.000 description 3
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 3
- 229960001334 Corticosteroids Drugs 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 3
- 108090000093 Leukotriene B4 receptors Proteins 0.000 description 3
- 102000003680 Leukotriene B4 receptors Human genes 0.000 description 3
- 102000038027 MAP kinase family Human genes 0.000 description 3
- 108091007472 MAP kinase family Proteins 0.000 description 3
- 239000000808 adrenergic beta-agonist Substances 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N al2o3 Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000001684 chronic Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000003883 cystic fibrosis Diseases 0.000 description 3
- 239000002308 endothelin receptor antagonist Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 230000002757 inflammatory Effects 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 3
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 3
- QVQMRAGGHIOTLV-UHFFFAOYSA-N 1,4-diazaspiro[5.5]undecane-5,9-dione Chemical compound C1CC(=O)CCC21C(=O)NCCN2 QVQMRAGGHIOTLV-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- RCORMCWYMRPHPO-UHFFFAOYSA-M 2,2-bis(3-fluorophenyl)-2-hydroxyacetate Chemical compound C=1C=CC(F)=CC=1C(C([O-])=O)(O)C1=CC=CC(F)=C1 RCORMCWYMRPHPO-UHFFFAOYSA-M 0.000 description 2
- ODELFXJUOVNEFZ-UHFFFAOYSA-M 2,2-diphenylpropanoate Chemical compound C=1C=CC=CC=1C(C([O-])=O)(C)C1=CC=CC=C1 ODELFXJUOVNEFZ-UHFFFAOYSA-M 0.000 description 2
- MAGCRYYXZYUDSY-UHFFFAOYSA-M 2-fluoro-2,2-diphenylacetate Chemical compound C=1C=CC=CC=1C(F)(C(=O)[O-])C1=CC=CC=C1 MAGCRYYXZYUDSY-UHFFFAOYSA-M 0.000 description 2
- LAPGMTOHOQPDGI-UHFFFAOYSA-N 4-amino-2,5-difluorobenzonitrile Chemical group NC1=CC(F)=C(C#N)C=C1F LAPGMTOHOQPDGI-UHFFFAOYSA-N 0.000 description 2
- DTZDZCNXNYMMOW-UHFFFAOYSA-M 9-hydroxyxanthene-9-carboxylate Chemical compound C1=CC=C2C(O)(C([O-])=O)C3=CC=CC=C3OC2=C1 DTZDZCNXNYMMOW-UHFFFAOYSA-M 0.000 description 2
- PUPWRKQSVGUBQS-UHFFFAOYSA-M 9-methylfluorene-9-carboxylate Chemical compound C1=CC=C2C(C)(C([O-])=O)C3=CC=CC=C3C2=C1 PUPWRKQSVGUBQS-UHFFFAOYSA-M 0.000 description 2
- CBNOKZSYCBHRAD-UHFFFAOYSA-M 9-methylxanthene-9-carboxylate Chemical compound C1=CC=C2C(C)(C([O-])=O)C3=CC=CC=C3OC2=C1 CBNOKZSYCBHRAD-UHFFFAOYSA-M 0.000 description 2
- 101710028063 APCS Proteins 0.000 description 2
- 206010001889 Alveolitis Diseases 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 108060001945 CRK Proteins 0.000 description 2
- 101710002223 CYSLTR1 Proteins 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229940105329 Carboxymethylcellulose Drugs 0.000 description 2
- 208000007451 Chronic Bronchitis Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229940012017 Ethylenediamine Drugs 0.000 description 2
- BPZSYCZIITTYBL-YJYMSZOUSA-N Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 description 2
- 229960001031 Glucose Drugs 0.000 description 2
- 102100002437 LTB4R Human genes 0.000 description 2
- 101710005170 LTB4R Proteins 0.000 description 2
- 102100012770 LTB4R2 Human genes 0.000 description 2
- 101710005169 LTB4R2 Proteins 0.000 description 2
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 2
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 2
- 102100016823 MAPK1 Human genes 0.000 description 2
- 101700083887 MAPK1 Proteins 0.000 description 2
- 102100005527 MAPK10 Human genes 0.000 description 2
- 101710029927 MAPK10 Proteins 0.000 description 2
- 102100000918 MAPK14 Human genes 0.000 description 2
- 102100005528 MAPK9 Human genes 0.000 description 2
- 101710029922 MAPK9 Proteins 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 101710028881 PSAP Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 208000009269 Pulmonary Emphysema Diseases 0.000 description 2
- 101710030983 RNF138 Proteins 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 102100001435 SH2D1A Human genes 0.000 description 2
- 101710013575 SH2D1A Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 101710029702 TICAM1 Proteins 0.000 description 2
- 101710021425 TRIM69 Proteins 0.000 description 2
- 102100003447 TRIM69 Human genes 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N Vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 2
- 206010047461 Viral infection Diseases 0.000 description 2
- 208000001756 Virus Disease Diseases 0.000 description 2
- OWGUSBISUVLUJF-SDNWHVSQSA-N [(E)-(2-hexylcyclopentylidene)amino]thiourea Chemical compound CCCCCCC1CCC\C1=N/NC(N)=S OWGUSBISUVLUJF-SDNWHVSQSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- VBQDSLGFSUGBBE-UHFFFAOYSA-N benzyl(triethyl)azanium Chemical compound CC[N+](CC)(CC)CC1=CC=CC=C1 VBQDSLGFSUGBBE-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical class OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 101710024775 erkB Proteins 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000004524 haematopoietic cell Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- XGZVLEAZGCUUPH-UHFFFAOYSA-N methylamino(methylimino)methanesulfonic acid Chemical compound CNC(=NC)S(O)(=O)=O XGZVLEAZGCUUPH-UHFFFAOYSA-N 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N n-methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 2
- 230000035778 pathophysiological process Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 2
- 125000005547 pivalate group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001184 potassium carbonate Substances 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical class CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 101710044770 sll1951 Proteins 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 239000002700 tablet coating Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000001173 tumoral Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- DXEXNWDGDYUITL-FXSSSKFRSA-N (8S,9R,10S,11S,13S,14S,17R)-17-ethylsulfanyl-9-fluoro-11-hydroxy-10,13-dimethyl-17-methylsulfanyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](SC)(SCC)[C@@]1(C)C[C@@H]2O DXEXNWDGDYUITL-FXSSSKFRSA-N 0.000 description 1
- VVBIFWHTQJEQQD-UHFFFAOYSA-N 1,4-diazaspiro[5.5]undecane Chemical compound C1CCCCC21NCCNC2 VVBIFWHTQJEQQD-UHFFFAOYSA-N 0.000 description 1
- MVCOAUNKQVWQHZ-UHFFFAOYSA-N 1-(5-Tert-Butyl-2-P-Tolyl-2h-Pyrazol-3-Yl)-3-[4-(2-Morpholin-4-Yl-Ethoxy)-Naphthalen-1-Yl]-Urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 MVCOAUNKQVWQHZ-UHFFFAOYSA-N 0.000 description 1
- GQMYQEAXTITUAE-UHFFFAOYSA-N 1H-indole-5-carboxamide Chemical compound NC(=O)C1=CC=C2NC=CC2=C1 GQMYQEAXTITUAE-UHFFFAOYSA-N 0.000 description 1
- ZMXHONJJTQSZKY-UHFFFAOYSA-M 2,2-bis(3,4-difluorophenyl)-2-hydroxyacetate Chemical compound C=1C=C(F)C(F)=CC=1C(C([O-])=O)(O)C1=CC=C(F)C(F)=C1 ZMXHONJJTQSZKY-UHFFFAOYSA-M 0.000 description 1
- YKZXWNCXGVYCKF-UHFFFAOYSA-M 2,2-bis(4-fluorophenyl)-2-hydroxyacetate Chemical compound C=1C=C(F)C=CC=1C(C([O-])=O)(O)C1=CC=C(F)C=C1 YKZXWNCXGVYCKF-UHFFFAOYSA-M 0.000 description 1
- CDOYOTAXUDCGFD-UHFFFAOYSA-N 2,2-difluoro-2-(3-methoxyphenyl)acetic acid Chemical group COC1=CC=CC(C(F)(F)C(O)=O)=C1 CDOYOTAXUDCGFD-UHFFFAOYSA-N 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- XCPPIJCBCWUBNT-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-2-[2-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]pyrimidin-4-yl]acetonitrile Chemical compound N=1C2=CC=CC=C2SC=1C(C#N)C(N=1)=CC=NC=1OCC(C=C1)=CC=C1CN1CCOCC1 XCPPIJCBCWUBNT-UHFFFAOYSA-N 0.000 description 1
- LUAASYCSMRTDFL-UHFFFAOYSA-N 2-(4-fluorophenyl)-1$l^{6},3$l^{6},2-benzodithiazole 1,1,3,3-tetraoxide Chemical compound C1=CC(F)=CC=C1N1S(=O)(=O)C2=CC=CC=C2S1(=O)=O LUAASYCSMRTDFL-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N 2-Pyrrolidone Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- ZMPRRFPMMJQXPP-UHFFFAOYSA-M 2-carboxybenzenesulfonate Chemical class OC(=O)C1=CC=CC=C1S([O-])(=O)=O ZMPRRFPMMJQXPP-UHFFFAOYSA-M 0.000 description 1
- KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 description 1
- ACGFJKWJHZJQCX-UHFFFAOYSA-N 240815-49-0 Chemical compound O=C1NC2=CC=CN=C2N2C1=CN=C2 ACGFJKWJHZJQCX-UHFFFAOYSA-N 0.000 description 1
- IOVGROKTTNBUGK-UHFFFAOYSA-N 4-[2-[[1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol Chemical compound C=1C=C(O)C=CC=1C(O)C(C)NCCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical class OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical group OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N 4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,2-diol Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- FBXGQDUVJBKEAJ-UHFFFAOYSA-N 4H-oxazin-3-one Chemical compound O=C1CC=CON1 FBXGQDUVJBKEAJ-UHFFFAOYSA-N 0.000 description 1
- IHOXNOQMRZISPV-YJYMSZOUSA-N 5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]azaniumyl]ethyl]-2-oxo-1H-quinolin-8-olate Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 IHOXNOQMRZISPV-YJYMSZOUSA-N 0.000 description 1
- XDBHURGONHZNJF-UHFFFAOYSA-N 6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=C(OCC)C(OCC)=CC=C1C1=NC(C=2N=C(C=CC=2)C(O)=O)=CS1 XDBHURGONHZNJF-UHFFFAOYSA-N 0.000 description 1
- PFEHTONZNYPYSP-UHFFFAOYSA-N 7-[2-[2-[3-[2-(2-chlorophenyl)ethylamino]propylsulfanyl]ethylamino]-2-hydroxyethyl]-4-hydroxy-3H-1,3-benzothiazol-2-one Chemical compound C=1C=C(O)C=2NC(=O)SC=2C=1CC(O)NCCSCCCNCCC1=CC=CC=C1Cl PFEHTONZNYPYSP-UHFFFAOYSA-N 0.000 description 1
- ZRDOWGBNGIHJTG-UHFFFAOYSA-M 9-(hydroxymethyl)xanthene-9-carboxylate Chemical compound C1=CC=C2C(CO)(C([O-])=O)C3=CC=CC=C3OC2=C1 ZRDOWGBNGIHJTG-UHFFFAOYSA-M 0.000 description 1
- BHEFSGMUMYBJRZ-UHFFFAOYSA-M 9-fluorofluorene-9-carboxylate Chemical compound C1=CC=C2C(C(=O)[O-])(F)C3=CC=CC=C3C2=C1 BHEFSGMUMYBJRZ-UHFFFAOYSA-M 0.000 description 1
- 229950006944 ATIZORAM Drugs 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 206010052613 Allergic bronchitis Diseases 0.000 description 1
- 206010049153 Allergic sinusitis Diseases 0.000 description 1
- OUJTZYPIHDYQMC-LJQANCHMSA-N Ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 description 1
- GVTLDPJNRVMCAL-UHFFFAOYSA-N Arofylline Chemical compound C1=2N=CNC=2C(=O)N(CCC)C(=O)N1C1=CC=C(Cl)C=C1 GVTLDPJNRVMCAL-UHFFFAOYSA-N 0.000 description 1
- LITNEAPWQHVPOK-FFSVYQOJSA-N Atizoram Chemical compound C1=C(O[C@@H]2[C@H]3CC[C@H](C3)C2)C(OC)=CC=C1C1CNC(=O)NC1 LITNEAPWQHVPOK-FFSVYQOJSA-N 0.000 description 1
- 108060001001 BRK1 Proteins 0.000 description 1
- 206010060945 Bacterial infection Diseases 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N Bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- 229950006785 Bentamapimod Drugs 0.000 description 1
- 229940050390 Benzoate Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N Betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 210000000013 Bile Ducts Anatomy 0.000 description 1
- GJPICJJJRGTNOD-UHFFFAOYSA-N Bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N Bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N Bricaril Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- CQFNOACVVKSEOJ-VBQPQCOESA-N Bronilide Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O CQFNOACVVKSEOJ-VBQPQCOESA-N 0.000 description 1
- 229960004436 Budesonide Drugs 0.000 description 1
- VOVIALXJUBGFJZ-VXKMTNQYSA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-VXKMTNQYSA-N 0.000 description 1
- 229950001167 Butixocort Drugs 0.000 description 1
- PDYTYRKWKWQHNC-AWEZNQCLSA-M C1NC(=C(C([O-])=O)CC)C[C@@H]1C1=CC=C(OC)C(OC2CCCC2)=C1 Chemical compound C1NC(=C(C([O-])=O)CC)C[C@@H]1C1=CC=C(OC)C(OC2CCCC2)=C1 PDYTYRKWKWQHNC-AWEZNQCLSA-M 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 Chemical class CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- WMBUVOLZSWTKMP-KQFGJPIXSA-N CEP-1347 Chemical compound C12=CC=C(CSCC)C=C2C2=C(CNC3=O)C3=C3C4=CC(CSCC)=CC=C4N4C3=C2N1[C@]1(C)[C@@H](C(=O)OOC)C[C@@H]4O1 WMBUVOLZSWTKMP-KQFGJPIXSA-N 0.000 description 1
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N CHEMBL1888176 Chemical class [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 description 1
- CFBUZOUXXHZCFB-OYOVHJISSA-N CHEMBL511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 1
- OATDVDIMNNZTEY-DAXLTYESSA-N C[N@@+]1(CCF)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1 Chemical class C[N@@+]1(CCF)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1 OATDVDIMNNZTEY-DAXLTYESSA-N 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- OFAIGZWCDGNZGT-UHFFFAOYSA-N Caramiphen Chemical compound C=1C=CC=CC=1C1(C(=O)OCCN(CC)CC)CCCC1 OFAIGZWCDGNZGT-UHFFFAOYSA-N 0.000 description 1
- 229960004160 Caramiphen Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KEMXXQOFIRIICG-UHFFFAOYSA-N Carbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(NC(N)=O)=C1 KEMXXQOFIRIICG-UHFFFAOYSA-N 0.000 description 1
- 229950010713 Carmoterol Drugs 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- CFBUZOUXXHZCFB-UHFFFAOYSA-N Cilomilast Chemical compound COC1=CC=C(C2(CCC(CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-UHFFFAOYSA-N 0.000 description 1
- 229950001653 Cilomilast Drugs 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N Clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 206010009887 Colitis Diseases 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- 229940109275 Cyclamate Drugs 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N Cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- HSDBULQDKRYING-UHFFFAOYSA-N Cyclopropyltropine Benzilate Chemical compound C1C(C2C3C2)N(C)C3CC1OC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 HSDBULQDKRYING-UHFFFAOYSA-N 0.000 description 1
- QIEPWCSVQYUPIY-LEKSSAKUSA-N Delta(1)-progesterone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 QIEPWCSVQYUPIY-LEKSSAKUSA-N 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229950005521 Doramapimod Drugs 0.000 description 1
- 102000001301 EGF receptors Human genes 0.000 description 1
- 108060006698 EGF receptors Proteins 0.000 description 1
- 210000002889 Endothelial Cells Anatomy 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N Endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- LSLYOANBFKQKPT-UHFFFAOYSA-N Fenoterol Chemical compound C=1C(O)=CC(O)=CC=1C(O)CNC(C)CC1=CC=C(O)C=C1 LSLYOANBFKQKPT-UHFFFAOYSA-N 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N Fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 210000000232 Gallbladder Anatomy 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 229940116364 Hard Fat Drugs 0.000 description 1
- OXLZNBCNGJWPRV-UHFFFAOYSA-N Hexoprenaline Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNCCCCCCNCC(O)C1=CC=C(O)C(O)=C1 OXLZNBCNGJWPRV-UHFFFAOYSA-N 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N Hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229950002451 Ibuterol Drugs 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N Indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 1
- 108010018976 Interleukin-8A Receptors Proteins 0.000 description 1
- 208000006897 Interstitial Lung Disease Diseases 0.000 description 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
- 108040008094 JUN kinase activity proteins Proteins 0.000 description 1
- 102100011311 KNG1 Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N Leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- YEESKJGWJFYOOK-IJHYULJSSA-N Leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N Levosalbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 1
- 229950008462 Lirimilast Drugs 0.000 description 1
- 206010025135 Lupus erythematosus Diseases 0.000 description 1
- 102100005531 MAPK8 Human genes 0.000 description 1
- 101710029924 MAPK8 Proteins 0.000 description 1
- JSJCTEKTBOKRST-UHFFFAOYSA-N Mabuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(C(F)(F)F)=C1 JSJCTEKTBOKRST-UHFFFAOYSA-N 0.000 description 1
- 229950004407 Mabuterol Drugs 0.000 description 1
- JGCMEBMXRHSZKX-UHFFFAOYSA-N Macitentan Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)NCCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 description 1
- 229940057948 Magnesium stearate Drugs 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229950001768 Milveterol Drugs 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 229960001664 Mometasone Drugs 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 210000003097 Mucus Anatomy 0.000 description 1
- OKFDRAHPFKMAJH-UHFFFAOYSA-N N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-8-(methanesulfonamido)dibenzofuran-1-carboxamide Chemical compound C=12C3=CC(NS(=O)(=O)C)=CC=C3OC2=C(OC(F)F)C=CC=1C(=O)NC1=C(Cl)C=NC=C1Cl OKFDRAHPFKMAJH-UHFFFAOYSA-N 0.000 description 1
- BMKINZUHKYLSKI-DQEYMECFSA-N N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[2-[4-[[(2R)-2-hydroxy-2-phenylethyl]amino]phenyl]ethylamino]ethyl]phenyl]formamide Chemical compound C1([C@@H](O)CNC2=CC=C(C=C2)CCNC[C@H](O)C=2C=C(NC=O)C(O)=CC=2)=CC=CC=C1 BMKINZUHKYLSKI-DQEYMECFSA-N 0.000 description 1
- HHRNQOGXBRYCHF-UHFFFAOYSA-N N-[2-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide Chemical compound CC(C)NCC(O)C1=CC=C(O)C(NS(C)(=O)=O)=C1 HHRNQOGXBRYCHF-UHFFFAOYSA-N 0.000 description 1
- HWYHDWGGACRVEH-UHFFFAOYSA-N N-methyl-N-(4-pyrrolidin-1-ylbut-2-ynyl)acetamide Chemical compound CC(=O)N(C)CC#CCN1CCCC1 HWYHDWGGACRVEH-UHFFFAOYSA-N 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- NDTKXJOMFWNZGE-UHFFFAOYSA-M OC1C2=CC=CC=C2C=2C=CC=C(C1=2)C(=O)[O-] Chemical compound OC1C2=CC=CC=C2C=2C=CC=C(C1=2)C(=O)[O-] NDTKXJOMFWNZGE-UHFFFAOYSA-M 0.000 description 1
- 229950000175 Oglemilast Drugs 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N Orciprenaline Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- 101700059544 PTGR1 Proteins 0.000 description 1
- CFJMRBQWBDQYMK-UHFFFAOYSA-N Pentoxyverine Chemical compound C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 CFJMRBQWBDQYMK-UHFFFAOYSA-N 0.000 description 1
- 229960003436 Pentoxyverine Drugs 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035669 Pneumonia aspiration Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 229940093430 Polyethylene Glycol 1500 Drugs 0.000 description 1
- 229940093429 Polyethylene Glycol 6000 Drugs 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N Pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960002288 Procaterol Drugs 0.000 description 1
- FKNXQNWAXFXVNW-BLLLJJGKSA-N Procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
- 208000010069 Prostatic Disease Diseases 0.000 description 1
- 208000008425 Protein Deficiency Diseases 0.000 description 1
- 208000005069 Pulmonary Fibrosis Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N Quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- WVLAAKXASPCBGT-UHFFFAOYSA-N Reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 description 1
- IXTCZMJQGGONPY-XJAYAHQCSA-N Rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 description 1
- 229950004432 Rofleponide Drugs 0.000 description 1
- 229960002586 Roflumilast Drugs 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N Roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- RUOGJYKOQBFJIG-UHFFFAOYSA-N SCH-351591 Chemical compound C12=CC=C(C(F)(F)F)N=C2C(OC)=CC=C1C(=O)NC1=C(Cl)C=[N+]([O-])C=C1Cl RUOGJYKOQBFJIG-UHFFFAOYSA-N 0.000 description 1
- 229950010289 SOTERENOL Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- VPMWDFRZSIMDKW-YJYMSZOUSA-N Salmefamol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 VPMWDFRZSIMDKW-YJYMSZOUSA-N 0.000 description 1
- 229950001879 Salmefamol Drugs 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- PHWXUGHIIBDVKD-UHFFFAOYSA-N Sitaxentan Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC=2C(=CC=3OCOC=3C=2)C)=C1Cl PHWXUGHIIBDVKD-UHFFFAOYSA-N 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Sodium cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N Stearyl alcohol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 101700038204 TGFA Proteins 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 229960000195 Terbutaline Drugs 0.000 description 1
- 229950002896 Tetomilast Drugs 0.000 description 1
- 229960000278 Theophylline Drugs 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- DQHNAVOVODVIMG-UHFFFAOYSA-M Tiotropium bromide Chemical class [Br-].C1C(C2C3O2)[N+](C)(C)C3CC1OC(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 DQHNAVOVODVIMG-UHFFFAOYSA-M 0.000 description 1
- 229950001669 Tipredane Drugs 0.000 description 1
- DHCOPPHTVOXDKU-UHFFFAOYSA-N Tofimilast Chemical compound C1CN2C(C=3SC=CC=3)=NN=C2C2=C1C(CC)=NN2C1CCCC1 DHCOPPHTVOXDKU-UHFFFAOYSA-N 0.000 description 1
- 229950003899 Tofimilast Drugs 0.000 description 1
- 102000006747 Transforming growth factor alpha Human genes 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N Triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229950004209 ZINTEROL Drugs 0.000 description 1
- 229960004764 Zafirlukast Drugs 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- XJBCFFLVLOPYBV-UHFFFAOYSA-N Zinterol Chemical compound C=1C=C(O)C(NS(C)(=O)=O)=CC=1C(O)CNC(C)(C)CC1=CC=CC=C1 XJBCFFLVLOPYBV-UHFFFAOYSA-N 0.000 description 1
- VHHCBEBSLNPGNV-QVKFZJNVSA-N [(1S,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-en-5-yl] 2,2-bis(3,4-difluorophenyl)-2-hydroxyacetate Chemical compound O([C@]12CC[C@@H](CC=C2)N1C)C(=O)C(O)(C=1C=C(F)C(F)=CC=1)C1=CC=C(F)C(F)=C1 VHHCBEBSLNPGNV-QVKFZJNVSA-N 0.000 description 1
- WVZUNVZUCHZCNO-TZIWHRDSSA-N [(1S,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-en-5-yl] 2,2-bis(4-fluorophenyl)-2-hydroxyacetate Chemical compound O([C@]12CC[C@@H](CC=C2)N1C)C(=O)C(O)(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 WVZUNVZUCHZCNO-TZIWHRDSSA-N 0.000 description 1
- VNMXIOPVMGTUPI-NFBKMPQASA-N [(1S,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-en-5-yl] 2,2-diphenylpropanoate Chemical compound O([C@]12CC[C@@H](CC=C2)N1C)C(=O)C(C)(C=1C=CC=CC=1)C1=CC=CC=C1 VNMXIOPVMGTUPI-NFBKMPQASA-N 0.000 description 1
- QIAWOUUTKDMGTE-UJXPALLWSA-M [(4S)-4-amino-5-[4-[4-[[2,4-dichloro-3-[(2,4-dimethylquinolin-8-yl)oxymethyl]phenyl]sulfonylamino]oxane-4-carbonyl]piperazin-1-yl]-5-oxopentyl]-trimethylazanium;chloride;hydrochloride Chemical compound Cl.[Cl-].C12=NC(C)=CC(C)=C2C=CC=C1OCC(C=1Cl)=C(Cl)C=CC=1S(=O)(=O)NC1(C(=O)N2CCN(CC2)C(=O)[C@@H](N)CCC[N+](C)(C)C)CCOCC1 QIAWOUUTKDMGTE-UJXPALLWSA-M 0.000 description 1
- HOAKOHHSHOCDLI-TUFAYURCSA-N [(8S,9S,10R,11S,13S,14S,17R)-11-hydroxy-10,13-dimethyl-3-oxo-17-(2-sulfanylacetyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CS)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O HOAKOHHSHOCDLI-TUFAYURCSA-N 0.000 description 1
- YPFLFUJKZDAXRA-UHFFFAOYSA-N [3-(carbamoylamino)-2-(2,4-dichlorobenzoyl)-1-benzofuran-6-yl] methanesulfonate Chemical compound O1C2=CC(OS(=O)(=O)C)=CC=C2C(NC(N)=O)=C1C(=O)C1=CC=C(Cl)C=C1Cl YPFLFUJKZDAXRA-UHFFFAOYSA-N 0.000 description 1
- WKHOPHIMYDJVSA-UHFFFAOYSA-N [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(2-methylpropanoyloxy)phenyl] 2-methylpropanoate Chemical compound CC(C)C(=O)OC1=CC(OC(=O)C(C)C)=CC(C(O)CNC(C)(C)C)=C1 WKHOPHIMYDJVSA-UHFFFAOYSA-N 0.000 description 1
- UNYBDCWLVBARRC-UHFFFAOYSA-O [NH3+]CCCCCN1CCNCC1 Chemical compound [NH3+]CCCCCN1CCNCC1 UNYBDCWLVBARRC-UHFFFAOYSA-O 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- ASMXXROZKSBQIH-VITNCHFBSA-N aclidinium Chemical class C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 ASMXXROZKSBQIH-VITNCHFBSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910001884 aluminium oxide Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229960002414 ambrisentan Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229960001692 arformoterol Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960003065 bosentan Drugs 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229940096338 carbetapentane Drugs 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 229960001386 carbuterol Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-M dichloroacetate Chemical class [O-]C(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 description 1
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 description 1
- JTXYEERBIZXLJC-DCJXKKNWSA-N ethyl (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCC)(O)[C@@]1(C)C[C@@H]2O JTXYEERBIZXLJC-DCJXKKNWSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- RNFSRGBKGWQTPO-SKXRKSCCSA-N icatibant Chemical compound NC(=N)NCCC[C@@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2SC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@H](CC3=CC=CC=C3C2)C(=O)N2[C@@H](C[C@@H]3CCCC[C@@H]32)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C[C@@H](O)C1 RNFSRGBKGWQTPO-SKXRKSCCSA-N 0.000 description 1
- 229960001062 icatibant Drugs 0.000 description 1
- 229960004078 indacaterol Drugs 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical class O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 229950008204 levosalbutamol Drugs 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229940054556 metaproterenol Drugs 0.000 description 1
- MEQKIBIRCVJSRK-UHFFFAOYSA-N methyl 2,2-bis(4-fluorophenyl)-2-hydroxyacetate Chemical compound C=1C=C(F)C=CC=1C(O)(C(=O)OC)C1=CC=C(F)C=C1 MEQKIBIRCVJSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- UJJLJRQIPMGXEZ-UHFFFAOYSA-M oxolane-2-carboxylate Chemical compound [O-]C(=O)C1CCCO1 UJJLJRQIPMGXEZ-UHFFFAOYSA-M 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CJPNOLIZCWDHJK-UHFFFAOYSA-N pentadecan-2-one Chemical compound CCCCCCCCCCCCCC(C)=O CJPNOLIZCWDHJK-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000001129 phenylbutoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229940075065 polyvinyl acetate Drugs 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M pyridine-4-carboxylate Chemical class [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229960002720 reproterol Drugs 0.000 description 1
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229960002578 sitaxentan Drugs 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000004441 surface measurement Methods 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 201000009594 systemic scleroderma Diseases 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- ARWWSIWJLRJSAH-UHFFFAOYSA-N tert-butyl 5,9-dioxo-1,4-diazaspiro[5.5]undecane-4-carboxylate Chemical compound O=C1N(C(=O)OC(C)(C)C)CCNC11CCC(=O)CC1 ARWWSIWJLRJSAH-UHFFFAOYSA-N 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940117960 vanillin Drugs 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Disclosed is crystalline 9-[4-(3-chloro-2-fluorophenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diazaspiro[5.5]undecan-5-one dimaleate of formula (I) optionally in the form of the tautomers thereof, wherein reflections in the X-ray powder diagram occur at dhkl values of 7.11, 5.77, 4.69, 4.36, 4.15, 3.85 and 3.61 Å, and has corresponding values 2theta of 12.43, 15.33, 18.92, 20.37, 21.38, 23.06 and 24.67. Also disclosed is a process for the stereoselective preparation of the crystalline compound of formula (I) starting from 1,4-cyclohexanedione-mono-ethyleneketal. Also disclosed is a process for the chlorination of tert-butyl (trans)-9-(4-hydroxy-7-methoxy-quinazolin-6-yloxy)-5-oxo-1-(2,2,2-trifluoro-acetyl)-1,4-diaza-spiro[5.5]undecane-4-carboxylate or tert-butyl (trans)-9-(4-oxo-7-methoxy-quinazolin-6-yloxy)-5-oxo-1-(2,2,2-trifluoro-acetyl)-1,4-diaza-spiro[5.5]undecane-4-carboxylate with a reactant selected from among N-chlorosuccinimide/triphenylphosphane oxalyl chloride, thionyl chloride, phosphorus oxychloride, phosphorus pentachloride, carbon tetrachloride/triphenylphosphane, dichlorotriphenylphosphorane and P,P-dichlorophenylphosphine oxide, to form tert-butyl (trans)-9-(4-chloro-7-methoxy-quinazolin-6-yloxy)-5-oxo-1-(2,2,2-trifluoro-acetyl)-1,4-diaza-spiro[5.5]undecane-4-carboxylate. Further disclosed are intermediates such as tert-butyl (trans)-9-(3-benzyl-7-methoxy-4-oxo-3,4-dihydro-quinazolin-6-yloxy)-5-oxo-1-(2,2,2-trifluoro-acetyl)-1,4-diaza-spiro[5.5]undecane-4-carboxylate and (trans)-9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1-(2,2,2-trifluoro-acetyl)-1,4-diaza-spiro[5.5]undecan-5-one hydrochloride. 3.85 and 3.61 Å, and has corresponding values 2theta of 12.43, 15.33, 18.92, 20.37, 21.38, 23.06 and 24.67. Also disclosed is a process for the stereoselective preparation of the crystalline compound of formula (I) starting from 1,4-cyclohexanedione-mono-ethyleneketal. Also disclosed is a process for the chlorination of tert-butyl (trans)-9-(4-hydroxy-7-methoxy-quinazolin-6-yloxy)-5-oxo-1-(2,2,2-trifluoro-acetyl)-1,4-diaza-spiro[5.5]undecane-4-carboxylate or tert-butyl (trans)-9-(4-oxo-7-methoxy-quinazolin-6-yloxy)-5-oxo-1-(2,2,2-trifluoro-acetyl)-1,4-diaza-spiro[5.5]undecane-4-carboxylate with a reactant selected from among N-chlorosuccinimide/triphenylphosphane oxalyl chloride, thionyl chloride, phosphorus oxychloride, phosphorus pentachloride, carbon tetrachloride/triphenylphosphane, dichlorotriphenylphosphorane and P,P-dichlorophenylphosphine oxide, to form tert-butyl (trans)-9-(4-chloro-7-methoxy-quinazolin-6-yloxy)-5-oxo-1-(2,2,2-trifluoro-acetyl)-1,4-diaza-spiro[5.5]undecane-4-carboxylate. Further disclosed are intermediates such as tert-butyl (trans)-9-(3-benzyl-7-methoxy-4-oxo-3,4-dihydro-quinazolin-6-yloxy)-5-oxo-1-(2,2,2-trifluoro-acetyl)-1,4-diaza-spiro[5.5]undecane-4-carboxylate and (trans)-9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1-(2,2,2-trifluoro-acetyl)-1,4-diaza-spiro[5.5]undecan-5-one hydrochloride.
Description
-[4-(3-chlorfluor-phenylamino)methoxy-quinazolinyloxy]-1,4-diazaspiro
[5.5]undecanone dimaleate, use thereof as a drug, and production thereof
The present invention relates to the compound of formula (I),
Cl NH O O
F O O
N OH OH
OH OH
N OMe
NH O O (I),
which has valuable pharmacological ties, particularly an inhibiting effect on signal
transduction mediated by tyrosine s, processes for stereoselectively preparing this
compound, particularly ceutical formulations suitable for inhalation and their use
for the treatment of diseases, particularly tumoral diseases, benign prostatic hyperplasia
and diseases of the lungs and airways.
BACKGROUND TO THE INVENTION
Quinazoline derivatives are known from the prior art as active substances for example for
the ent of tumoral diseases and also diseases of the lungs and airways. Processes
for ing quinazoline tives are described in WO03082290 and WO07068552.
WO2009098061 discloses the base (compound (II)) of the dimaleate salt according to the
invention und (I)).
The aim of the present invention is to provide of 9-[4-(3-chlorofluoro-a salt
phenylamino)methoxy-quinazolinyloxy]-1,4-diaza-spiro[5.5]undecanone which
by virtue of its pharmaceutical efficacy as a tyrosine-kinase inhibitoris le for use in
the therapeutic field, i.e. for the treatment of pathophysiological processes that are caused
by the hyperfunction of tyrosine-kinases.
(9797753_1):KZA
The compound prepared in the present invention is supposed to meet the requirements for
physical and chemical stability and other properties, such as for example crystalline
stability, the absence of polymorphism and low hygroscopicity, particularly with regard to
the absence of polymorphism, that are imposed on an active substance of a medicament.
A further aim of the present invention is to provide a stereoselective process for preparing
the nd according to the invention.
DESCRIPTION OF THE DRAWINGS
Figure 1: X-ray powder diagram of compound (I)
Figure 2: DSC/TG schemes of compound (I)
Figure 3: Sorption isotherms of compound (I): a.) kinetic plot, b.) isothermic plot
Y OF THE INVENTION
A first aspect of the invention es for a crystalline compound of formula (I)
Cl NH O O
F O O
N OH OH
OH OH
N OMe
NH O O (I),
optionally in the form of the tautomers thereof,
wherein reflections in the X-ray powder diagram occur at dhkl values of 7.11, 5.77, 4.69,
4.36, 4.15, 3.85 and 3.61 Å.
A second aspect of the invention es for a crystalline nd according tothe
first aspect of the invention for use as a ment.
A third aspect of the ion provides foruse of a crystalline compound according to
the first aspect of the invention for the manufacture of the a medicament for the treatment
of inflammatory or allergic diseases of the airways.
(9797753_1):KZA
A fourth aspect of the invention provides for a process for the stereoselective preparation
of the compound of formula (I) according to the first aspect of the invention, optionally in
the form of the tautomers thereof:
Cl NH O O
F O O
N OH OH
OH OH
N OMe
HN O O (I),
wherein the process comprises reaction steps (A) to (M), n
(A) is the reaction of 1,4-cyclohexanedione-mono-ethyleneketal with
ethylenediamine and chloroform to form a compound of formula (1)
(1),
(B) is the reaction of a nd of formula (1) to form the compound of
formula (2)
O O
x HCl HN
(2),
(C) is the reaction of a compound of formula (2) with bases selected from among
NaOtBu, KOtBu and NaOEt , , K2CO3, Li2CO3 and Na2CO3 to form the compound
of formula (3)
O O
(D) is the reaction of a compound of formula (3) with the protective group t
di-tert-butyldicarbonate in combination with (4-(dimethylamino)-pyridine (DMAP) to
form the compound of formula (4)
O O O
N O
(10257817_1):KZA
(E) is the reduction of a compound of formula (4) with NaBH4 or LiBH4 to form the
compound of formula (5)
HO O O
N O
(F) is the reaction of a compound of formula (5) with trifluoroacetic anhydride
to form a compound of formula (6)
HO O O
N O
O N
F F (6)
(G) is the on of a compound of formula (6) with a compound of formula (13)
and with a reagent selected from among triphenylphosphine/ diisopropyl
azodicarboxylate, triphenylphosphine/ diethyl arboxylate and tributylphosphine/
azodicarbonyl)dipiperidine to form a compound of formula (7)
N O (13)
O O O
N O
N O
O N
F F (7)
(H) is the reaction of a compound of formula (7) in the presence of Pd/C or Pd(OH)2
to form a compound of formula (8a) or its tautomeric form (8b),
O O O
N O
N O
O N
F F (8a)
(10257817_1):KZA
O O O
N O
N O
O N
F F (8b)
(I) is the chlorination of the compound of formula (8a) or (8b) with a nt
selected from among N-chlorosuccinimide/triphenylphosphane oxalyl chloride, thionyl
chloride, phosphorus oxychloride, phosphorus pentachloride, carbon
tetrachloride/triphenylphosphane, dichlorotriphenylphosphorane and P,P-dichlorophenylphosphine
oxide, to form a nd of formula (9)
O O O
N O
N O
O N
(9) F F
(J) + (K) is the reaction of the compound of formula (9) with
3-chlorofluoroaniline and the cleaving of a protective group to form a compound of
formula (11) or (11A)
Cl NH
F O O
N O
O N
F F (11)
Cl NH
F O O
N O
O N
F F x HCl (11A)
(10257817_1):KZA
or instead of steps (J+K) optionally steps (N+O) may be used, wherein
(N+O) is the cleaving of a protective group of the compound of formula (9) to form the
compound of formula (12) and subsequent reaction with 3-chlorofluoroaniline to form
the compound of formula (11) or (11A)
O O
N O
O N
F F
(12),
(L) is the cleaving of another protective group with a reagent selected from among
ethanolamine, ammonia and Ba(OH) to form the compound of a (II)
Cl NH
F O O
N OMe
(II)
(M) is the reaction of the compound of formula (II) with two equivalents of maleic
acid to form a compound of formula (I), ally in the form of the tautomers thereof,
Cl NH O O
F O O
N OH OH
OH OH
N OMe
HN O O
(I),
wherein process steps (A) to (M) take place successively in the sequence specified and
Step (M) is ed by crystallization and isolation of the compound of a (I).
A fifth aspect of the invention es for a process for the stereoselective preparation of
a compound of formula (I), wherein the process consists of process steps as defined the
fourth aspect of the invention (I), (J), (K), (L), and (M) or of s steps (I), (N), (O),
(L) and (M), wherein the process steps (I) to (M) in each case take place successively in
the sequence specified.
(10257817_1):KZA
A sixth aspect of the invention provides for a process for the stereoselective preparation
of a compound of formula (II), wherein the process consists of process steps as defined in
the fourth aspect of the invention (I), (J), (K) and (L), or of s steps (I), (N), (O)
and (L), wherein the process steps (I) to (L) in each case take place successively in the
sequence specified.
A h aspect of the invention provides for a s for the chlorination of a
compound of Formula (8a) or (8b)
O O O
N O
N O
O N
F F (8a)
O O O
N O
N O
O N
F F (8b)
with a reactant selected from among N-chlorosuccinimide/triphenylphosphane oxalyl
chloride, thionyl chloride, phosphorus oride, phosphorus pentachloride, carbon
tetrachloride/triphenylphosphane, dichlorotriphenylphosphorane and P,P-dichlorophenylphosphine
oxide, to form a compound of formula (9)
O O O
N O
N O
O N
(9) F F .
(10257817_1):KZA
An eighth aspect of the invention provides for an intermediate of formula (7)
O O O
N O
N O
O N
F F (7)
optionally in the form of the tautomers f.
A ninth aspect of the invention provides for an intermediate of formula (8a) or (8b),
O O O
N O
N O
O N
F F
(8a)
O O O
N O
N O
O N
F F (8b)
optionally in the form of the tautomers thereof.
A tenth aspect of the invention provides for an ediate of formula (9),
O O O
N O
N O
O N
(9) F F
optionally in the form of the tautomers thereof.
(10257817_1):KZA
An th aspect of the ion provides for an ediate of formula (11) or (11A),
Cl NH
F O O
N O
O N
F F (11)
Cl NH
F O O
N O
O N
F F x HCl (11A)
optionally in the form of the tautomers thereof.
DETAILED DESCRIPTION OF THE INVENTION
The present invention solves the above-mentioned problems by providing the compound
of formula (I) that is suitable in particular for oral administration, which is highly
crystalline, has low hygroscopicity and low polymorphism, the pharmaceutical
formulation thereof and the method of synthesis described hereinafter. By crystalline
stability is meant, within the scope of the present invention, that X-ray powder diagrams
of the compound of formula (I) have sharp reflections with high intensity up to the upper
2 Θ range, preferably up to 20 – 40 ° 2 Θ.
By low hygroscopicity is meant, within the scope of the present invention, that in sorption
experiments on the nd of formula (I) a water uptake of less than 1 % is ed
in the humidity range of 10 – 90 % investigated.
By low polymorphism is meant, within the scope of the t invention, that after
recrystallisation from different solvents of the nd of formula (I) a maximum of
other crystal modifications, preferably a maximum of 3 other crystal modifications,
particularly preferably no other crystal modifications are obtained.
(10257817_1):KZA
The invention relates to a compound of a (I)
optionally in the form of the ers, es or hydrates thereof.
A crystalline compound of formula (I) is preferred wherein reflections occur in the X-ray
powder diagram with dhk. values of 7.11, 5.77, 4.69, 4.36, 4.15, 3.85 and 3.61 A.
The ion further relates to the mentioned compound for use as a medicament,
preferably for the treatment of inflammatory or allergic diseases of the ainNays, particularly
preferably for the treatment of chronic obstructive bronchitis (COPD) and/or chronic bron-
chitis.
It is also preferable to use the compound of formula (I), the disease in question being one
that is selected from among acute bronchitis, bronchitis caused by ial or viral infec-
tion or fungi or helminths, allergic bronchitis, toxic bronchitis, asthma (intrinsic or allergic),
paediatric asthma, iectasis, allergic alveolitis, allergic or non-allergic rhinitis,
chronic sinusitis, cystic fibrosis or mucoviscidosis, alpha—1-antitrypsin deficiency, cough,
pulmonary emphysema, interstitial lung diseases, alveolitis, hyperreactive airways, nasal
polyps, pulmonary oedema, pneumonitis of different origins, e.g. radiation-induced or
caused by aspiration or infectious pneumonitis, collagenoses such as lupus erythema-
todes, systemic scleroderma, sarcoidosis and Boeck’s disease, and for treating complica-
tions in asthma and COPD triggered by viral, bacterial or other causes, for treating viral or
bacterial infections of the s or lungs.
It is also red to use the compound of formula (I) in cases of inflammatory or allergic
complaints in which autoimmune reactions are involved.
It is also preferred to use the compounds of formula (I) in cases of a disease in the form of
benign or malignant tumours.
The invention further s to a process for the stereoselective preparation of the com-
pound of formula (I), optionally in the form of the tautomers, solvates or hydrates thereof:
(I),
the process comprising reaction steps (A) to (M), wherein
(A) denotes the reaction of 1,4-cyclohexanedione-mono--ethyleneketal to form
a compound of formula (1)
(1),
(B) is the reaction of a compound of formula (1) to form the compound of for-
mula (2)
(C) is the on of a compound of a (2) to form the compound of for-
mula (3)
(D) is the reaction of a compound of formula (3) with a protective
group reagent
to form the compound of formula (4)
0weO O
(4),
(E) is the reduction of a compound of formula (4) to form the compound of for-
mula (5)
H0,“@N0 JOL0%
(F) is the reaction of a compound of formula (5) to form a compound of a
(G) is the reaction of a compound of formula (6) with a nd of formula
(13) to form a compound of formula (7)
cnfimOH
(13)
jofinio+
l EINQ
F F (7)
(H) is the reaction of a compound of formula (7) to form a compound of formula
(8a) or its tautomeric form (8b),
F F
(8a)
F F
(8b)
(I) is the chlorination of the compound of formula (8a) or (8b) to form a com-
pound of formula (9)
F F
(J) + (K) are the reaction of the compound of formula (9) with
3-chloro—2—fluoraniline and the cleaving of a protective group to form a compound
of a (11) or (11A)
l o N
F F
x HCI (11A)
(L) is the cleaving of another protective group to form the compound of formula
(II)
(M) is the reaction of the compound of formula (II) with maleic acid to form a
compound of formula (I), optionally in the form of the tautomers, solvates or hy-
drates thereof,
while process steps (A) to (M) take place successively in the sequence ted.
The invention further relates to a process for the stereoselective preparation of the com-
pound of formula (I), optionally in the form of the tautomers, es or hydrates thereof,
comprising process steps (A) to (M),
wherein process steps (J+K) are replaced by steps (N+O), where
(N+O) is the cleaving of a protective group of the compound of formula (9) to form
the compound of a (12) and subsequent reaction with 3-chlorofluoraniline
to form the compound of formula (11) or (11A)
In a preferred process for the stereoselective ation of a compound of formula (I),
the process consists of s steps (I), (J), (K), (L), and (M) or of process steps
(I),(N), (O), (L) and (M), while process steps (I) to (M) in each case take place suc-
cessively in the order indicated.
r preferred process for the stereoselective preparation of a compound of formula
(II) is characterised in that the process consists of process steps (I), (J), (K) and
(L), or of process steps (I),(N), (O) and (L), while process steps (I) to (L) in each
case take place successively in the order indicated.
Particularly preferred is process step (G).
Also particularly preferred is process step (I).
The invention r relates to the intermediate of formula (6), optionally in the form of the
tautomers, solvates or hydrates thereof.
The invention further relates to the intermediate of formula (7), optionally in the form of the
tautomers, solvates or hydrates thereof.
The invention further relates to the intermediate of formula (8), optionally in the form of the
tautomers, solvates or hydrates thereof.
The invention further relates to the intermediate of formula (9), optionally in the form of the
tautomers, solvates or hydrates thereof.
The invention further relates to the intermediate of formula (11) or (11A), ally in the
form of the tautomers, es or hydrates thereof.
The invention further s to a pharmaceutical composition containing a compound of
formula (I). An orally administered pharmaceutical ition containing a compound of
formula (I) is preferred.
In another aspect the ion relates to medicament ations which contain, in ad-
dition to a compound of a (I) according to claim 1, as a further active sub-
stance, one or more compounds selected from among the categories of the be-
tics, anticholinergics, corticosteroids, PDE4—inhibitors, LTD4-receptor an-
tagonists, LTB4-receptor antagonists, inhibitors of MAP kinases, bradykinin recep—
tor antagonists, endothelin receptor antagonists, CXCR1 and/ or CXCR2 receptor
antagonists, and antitussives, or double or triple combinations f.
In process steps A, C to L and N alternative reagents may be used, which are selected
from among the reagents listed below:
10 2012/051298
In process step
A: in addition to ethylenediamlne and chloroform :
ably benzyltriethylammonium chloride /NaOH, tetrabutylammonium de/
KOH, benzyltriethylammonium chloride /KOH,_tetrabutylammonium chloride/
NaOH, particularly preferably benzyltriethylammonium de/ NaOH;
preferably alkoxide bases selected from among NaO‘Bu, KO‘Bu and NaOEt , car-
bonate bases selected from among Cs2C03, K2C03, Li2C03 and Na2C03, particu-
larly preferably sodium methoxide;
in addition to di-tert—butyldicarbonate and DMAP (4-(dimethylamino)—pyridine):
preferably K2C03,Cs2CO3, Li2C03 and Na2C03, particularly preferably K2C03;
preferably NaBH4 and LiBH4, particularly preferably NaBH4;
in on to oroacetic anhydride:
as base preferably trlethylamine, Hijnig base, N-methylmorpholine and N,N-
laniline, particularly preferably triethylamine;
in addition to 3-benzylhydroxymethoxy—3H—quinazolinone:
preferably triphenylphosphine/ diisopropyl azodicarboxylate, triphenylphosphine/
diethyl azodicarboxylate, tributylphosphine/ 1,1'-(azodicarbonyl)dipiperldine, par-
ticularly preferably triphenylphosphlne/ diisopropyl azodicarboxylate;
sts, preferably selected from among Pd/C and Pd(OH)2 , particularly prefera-
bly Pd/C;
preferably N-chlorosuccinimide/triphenylphosphane (in combination), oxalyl chlo-
ride, thionyl chloride, phosphorus oxychloride, phosphorus pentachloride, carbon
tetrachloride/triphenylphosphane, dichlorotriphenylphosphorane and P,P-dichloro-
phenylphosphine oxide, ularly ably N-chlorosuccinimide/ triphenylphos—
phane (in combination);
J+K: in addition to 3-chlorofluooraniline:
preferably HCl, methanesulphonic acid, ethanesulphonic acid, p-toluenesulphonic
acid and HBr, particularly preferably HCI;
preferably ethanolamine, ammonia and Ba(OH)2, particularly preferably ethanola—
mine;
|+N: preferably N-chlorosuccinimide/triphenylphosphane (in combination), HCl, oxalyl
chloride, thionyl chloride, phosphorus oxychloride, phosphorus pentachloride, car-
bon hloride/trlphenylphosphane, dichlorotriphenylphosphorane, P,P-dichloro-
phenylphosphine oxide, methanesulphonic acid, ethanesulphonic acid, p-
toluenesulphonic acid and HBr, particularly preferably N-
chIorosuccinimide/triphenylphosphane (in combination) and HCI.
The use of the following ts selected from the group specified in each
case is pre-
ferred in the process steps described above:
In process step
A: CH2CI2, CHCI3, THF (tetrahydrofuran) and dioxane;
B: HOAc, dioxane, H20 and aqueous solutions of the ing solvents selected from
among EtOH, THF, iPrOH, MeOH, NMP (N-methyIpyrrolidone) and DMF (dimethylfor-
mamide);
C: ACN (CH3CN), EtOH, MeOH, iPrOH, H20, THF and NMP;
D: ACN, EtOH and NMP;
E: H20, MeOH, EtOH, THF and e;
F: Me-THF, THF, toluene, CH2CI2 and dioxane;
G: THF, NMP, dioxane, DMF and CH2CIZ;
H: iPrOH, dioxane, EtOH, MeOH, THF and NMP;
I: dioxane/ACN and THF/dioxane;
J: ACN, e, THF and EtOH;
K: ACN, dioxane, THF and EtOH;
L: EtOH, MeOH, iPrOH and dioxane;
M: EtOH, MeOH and H20;
N: dioxane/ACN and THF/dioxane
O: EtOH, n-PrOH, dioxane and NMP
The s steps described above are preferably carried out in the following temperature
ranges:
In process step:
A: preferably -15 to 40°C, particularly preferably 0 to 20°C;
B: preferably 0 to 100°C, particularly preferably 75 to 100°C;
C: preferably 0 to 65°C, particularly preferably 15 to 30°C;
D: preferably 10 to 80°C, particularly preferably 15 to 35°C;
E: preferably 0 to 40°C, particularly preferably 0 to 15°C;
F: ably —10 to 60°C, particularly ably 0 to 35°C;
G: preferably 10 to 65°C, particularly preferably 45 to 60°C;
H: preferably 20 to 85°C, ularly preferably 70 to 85°C;
I: preferably 20 to 100°C, particularly preferably 70 to 95°C;
J: preferably 20 to 100°C, particularly preferably 50 to 85°C;
K: ably 20 to 100°C, particularly preferably 50 to 85°C;
L: preferably 50 to 80°C, particularly preferably 70 to 80°C;
M: ably 0 to 75°C, particularly preferably 0 to 70°C.
N: preferably 20 to 100°C, particularly preferably 50 to 85°C;
0: preferably 50 to 100°C, particularly ably 70 to 80°C;
Preferably, protective groups selected from among benzyl, Cbz, trifluoracetyl and Boc,
particularly trifluoracetyl and Boc, are used.
The abbreviation Boc used in the above formulae denotes tertiary butyl carbamate and
Cbz denotes benzyloxycarbonyl.
Scheme 1 illustrates the synthesis according to the invention. All the compounds are
shown in the form of their bases.
Scheme 1 (part 1 of 2) sis of compound (I)
H0,“ 0 j: o o o
N ‘— WNJLo/k
_ 0%
o QQ
F3: (6)
F F o
\N o/
(13)
(EARN”O U» AO O O H
N o
WO 04206 14
Scheme 1 (part 2 of 2)
(10) II: F (9) F F
IO ,1) N o 5
I :i'k)
(11) ii
The following Examples serve to illustrate the processes carried out by
way of example for
preparing the compound of formula (I). These Examples are to be understood as being
an illustration of the invention, t limiting it to their t-matter.
Example 1
1 xa-9,12-diaza-dispiro[4.2.5.2]pentadecanone
Process step A
.1 kg of 50% sodium hydroxide solution are added dropwise at 5°C to a e of 437
g benzyltriethylammonium de and 2700 ml ethylenediamine in 19.2 L dichloro-
methane. Then a solution of 6000 g of 1,4-cyclohexanedione-mono-ethyleneketal and
6100 g chloroform in 4.8 L dichloromethane within the next 4.5 h is added dropwise at 5-
15°C. The dropping funnel is rinsed with 3 L dichloromethane. After 15 h, 18 L water and
39 L dichloromethane are added at 15-25°C. The phases are separated and the
aqueous
phase is extracted with 20 L dichloromethane. The combined organic phases are concen-
trated by distillation. After 72 L t have been distilled off, 48 L isopropanol are added
to the suspension and then a further 30 L solvent are distilled off. After cooling to 3°C the
precipitate is filtered off and washed twice with 7.5 L cold isopropanol. After drying at
50°C in vacuo, 6144 g of product is obtained.
Mass spectrum (ESP): m/z = 227 [M+H]+
Example 2
1,4-diaza-spiro[5.5]undecane;5,9-dione
Omm,0
Process step B
14.5 kg of 4M HCI in dioxane are added dropwise within 15 min to 6085 g oxa-9,12-
diaza-dispiro[4.2.5.2]pentadecanone in 25 kg acetic acid at 80-100°C. The dropping
funnel is rinsed with 3 kg acetic acid. After 140 min the sion is cooled to 20°C.
After 2h the precipitate is filtered off and washed twice with 12 L dioxane. After drying at
60°C in vacuo, 5333 g of product is obtained as the hydrochloride.
Mass spectrum (ESP): m/z = 183 [M+H]+
Process step C
5200 g of 1,4—diaza-spiro[5.5]undecane-5,9-dione hydrochoride in 52 L acetonitrile are
combined with 4370 ml 30% sodium methoxide solution in methanol at RT within 3h. The
dropping funnel is rinsed with 1 L methanol. 250 g sodium carbonate are added and the
mixture is stirred for 16 h. 30 L solvent are distilled off and after the addition of 20 L ace-
ile the suspension is filtered. The filter cake is washed with 10 L acetonitrile. 22 L
solvent are distilled off from the filtrate and the residue that ns the product is further
d directly in the next step.
Example 3
tert-butyl oxo-1,4—diaza-spiro[5.5]undecanecarboxylate
Process step D
6573 g potassium carbonate and 145 g 4—(dimethylamino)—pyridine are added to the resi-
due from the previous mixture which contains the 1,4-diaza-spiro[5.5]undecane-5,9—dione.
Then within 30 min 6487 g di-tert—butyldicarbonate in 8 L acetonitrile is added se.
The dropping funnel is rinsed with 2 L acetonitrile. After 100 min the mixture is added to
L water at 10°C. it is rinsed with 2 L water, 5 L acetonitrile and 16 L toluene. After
phase tion the organic phase is combined with 10 L toluene. 55 L solvent are dis-
tilled off. After the addition of 30 L methylcyclohexane and 10 L toluene the mixture is in-
oculated with product and the suspension is stirred for 14 h at 20-30°C. 20 L methylcyclo-
hexane are added and the mixture is cooled to -5°C. After 2.5h the precipitate is filtered
off and washed with 10 L methylcyciohexane. After drying at 50°C in vacuo, 5160 g of
product is obtained.
Mass spectrum (ESF): m/z = 283 [M+H]+
Example 4
tert—butyl (cis)-9—hydroxyoxo-1,4-diaza-spiro[5.5]undecane-4—carboxylate
Process step E
201 g sodium borohydride in 5 L water are added dropwise at 3°C within 17 min to a mix-
ture of 5000 g of tert-butyl 5,9-dioxo-1,4-diaza-spiro[5.5]undecane-4—carboxylate in 35 L
water. The ng funnel is rinsed with 1.4 L water. After 15 min, 30 L methyl-
tetrahydrofuran are added. After the addition of 10 L of sat. potassium carbonate solution
the phases are separated and the aqueous phase is extracted with 20 L methyl-
tetrahydrofuran. The combined organic phases are washed with 1 L sat. saline solution.
The organic phase is separated off and d with 27.5 L -tetrahydrofuran. 55 L
solvent are distilled off. Then 15 L methyl-tetrahydrofuran are added and 15 L solvent are
distilled off. Then 20 L methyl-tetrahydrofuran are added and 20 L solvent are distilled off.
Then 20 L methyl-tetrahydrofuran are added and 20 L solvent are led off. The e
which contains the product is further reacted directly in the next step.
Mass spectrum (ESF): m/z = 285 [M+H]+
Example 5
tert-butyl (cis)—9—hydroxy—5-oxo(2,2,2-trifluoro-acetyl)—1 ,4-diaza-spiro[5.5]undecane
carboxylate
Ho,, 0 JOL
N OJ?
0 N\/I;
F F
(6)
s step F
11.1 L triethylamine are added to the organic phase from the previous mixture. Then 5170
ml trifluoroacetic anhydride are added dropwise within 30 min at 3-25°C. After 15 min
12.4 L ol are added. After 1h, 30 L solvent are distilled off in vacuo. Then 15.3 L
methanol are added and 8 L of solvent are distilled off in vacuo. 12.4 L methanol are
added and 35 L water are added se at 1-10°C within 50 min. After 1h at 2°C the
precipitate is centrifuged off and washed with 10 L of a 2:1 mixture of water and methanol
and then again washed with 10 L water. After drying at 55°C in the circulating air dryer
5299 g of product is obtained as a cis/trans mixture.
This crude product is suspended in 70 L toluene. Then 500 ml solvent are distilled off and
then 10 L toluene are added. The solution is 'and at 52°C it is inoculated with prod-
uct. After 3h at 1°C the precipitate is centrifuged off and washed with 8 L cold toluene.
After drying at 55°C in vacuo 4398 g of product is obtained, which still contains .
4% trans product.
Mass spectrum (ESP): m/z = 381 [M+H]+
Example 6
tert-butyl (trans)(3-benzyl-7—methoxy—4—oxo-3,4-dihyd ro-quinazolinyloxy)oxo—1 -
(2,2,2—trifluoro—acetyl)-1 ,4-diaza-spiro[5.5]undecane—4-carboxylate
l oiwd
F F
(7)
Process step G
2471 ml diisopropyl azodicarboxylate is added dropwise, within 100 min, to a mixture of
3500 g tert-butyl (cis)—9—hydroxy-5—oxo—1-(2,2,2-trifluoro—acetyl)—1 ,4-diaza-
.5]undecane—4—carboxylate, 2362 g 3-benzylhydroxy-7—methoxy-3H—quinazolin-4—
one and 3292 g triphenylphosphine in 45 L tetrahydrofuran at 50-55°C. The dropping fun-
nel is rinsed with 4 L tetrahydrofuran and 30 L solvent are distilled off in vacuo. Then, dur-
ing the continuous addition of 60 L ethanol, a further 30 L solvent are led off at normal
pressure. It is inoculated with product and left to cool slowly to RT. After 19 h the i-
tate is filtered off and washed with 15 L ethanol. After drying at 50°C in vacuo, 4710 g of
product is obtained.
Mass spectrum (ESP): m/z = 645 [M+H]+
Example 7
tert-butyl (trans)(4—hydroxymethoxy-quinazolin-6—yloxy)—5-oxo(2,2,2-trifluoro-
acetyl)—1,4-diaza—spiro[5.5]undecane—4-carboxylate
0H 0
o o o o o o
N/ HN
N oU/HJLA $(Z UAMV— N o
'01”F ”IV—F
(8a) F F F F
(8b)
Process step H
470 g palladium (10%) on al are added to a mixture of 47009 tert-butyl (trans)—9—(3—
benzylmethoxy—4—oxo-3,4-dihydro—quinazolinyloxy)oxo(2,2,2-trifluoro-acetyl)-
1,4-diaza-spiro[5.5]undecane—4-carboxylate in 33 L isopropanol and 33 L dioxane. After 4
h hydrogenation at 80°C the mixture is filtered at 60°C and washed with a mixture of 10 L
isopropanol and 10 L dioxane. 58 L t are distilled off from the filtrate in vacuo and
32 L tert-butylmethylether are added. After 2 h at 0-5°C the precipitate is filtered off and
washed with 15 L tert-butylmethylether. After drying at 50°C in vacuo 4153 g of product is
obtained.
Mass spectrum (ESP): m/z = 555 [M+H]+
Example 8
tert-butyl (trans)—9-(4-chloromethoxy-quinazolinyloxy)—5-oxo—1-(2,2,2-trifluoro-acetyl)-
1 ,4-diaza-spiro[5.5]undecanecarboxylate
(9)
Process step I
1590 g N-chlorosuccinimide in 20 L acetonitrile are added to a mixture of 5500
g tert-butyl
(trans)—9-(4-hydroxymethoxy-quinazolinyloxy)—5-oxo—1-(2,2,2—trifluoro—acetyl)-1 ,4-
diaza-spiro[5.5]undecane—4-carboxylate and 3122 g triphenylphosphine in 24 L dioxane at
60°C within one minute. The ng funnel is rinsed with 4 L acetonitrile and the mixture
is heated to 80-90°C for 30 min. The mixture containing the product is used directly in the
next step.
Example 9
utyl (trans)—9-[4-(3-chloro—2-fluoro-phenylamino)methoxy-quinazolin-6—yloxy]— 5-
oxo(2,2,2—trifluoro—acetyl)—1 ,4-diaza-spiro[5.5]undecanecarboxylate
(10)
(trans)—9-[4-(3-chlorofluoro-phenylamino)—7—methoxy—quinazolinyloxy]-1—(2,2,2—
trifluoro—acetyl)—1,4-diaza-spiro[5.5]undecanone hydrochloride
Process step J+K
After 20 min at 50-60°C 1733 g 3-chloro—2—fluoranilin are added to the mixture. The drop-
ping funnel is rinsed with 2 L acetonitriie. Then 7.8 kg 4 M hydrochloric acid in dioxane are
added and the mixture is stirred for 45 min at 55-80°C. After cooling to 1°C the precipitate
is filtered off and washed with 10 L ethanol. The precipitate is suspended in 40 L l
and ed with 290 g 3-chloro—2—fluoroaniline. The suspension is stirred for 45 min at
C and then for 13 h at RT. The precipitate is filtered off and washed with 10 L etha-
nol. After drying at 60°C in vacuo 4853 g of product is obtained as the hydrochloride.
Mass spectrum (ESP): m/z = 582 [M+H]+
Process step 0
A e of 3.42 g (trans)—9-(4-ch|oromethoxy-quinazolinyloxy)—1-(2,2,2-trif|uoro-
)-1,4-diaza—spiro[5.5]undecan-5—one and 1.25 g 3-chIorofluoroaniline in 40 ml of
ethanol is heated to 80°C for 2 h. After the suspension has been cooled to 20°C and
stirred for 16 h the precipitate is ed off and washed with 10 mL ethanol and 10 mL
tert-butylmethylether. After drying at 100°C in vacuo, 3.28 g of product is obtained.
Mass spectrum (ESP): m/z = 582 [M+H]+
Example 10
(trans)[4-(3-chIoro—2-fluoro-phenylamino)—7—methoxy-quinazoiin-6—yloxy]-1 ,4—diaza-
spiro[5.5]undecanone
Process step L
A mixture of 4700 g (trans)—9—[4—(3-ch|orof|uoro-pheny|amino)methoxy—quinazolin
yioxy](2,2,2-trifluoro-acetyl)—1,4-diaza-spiro[5.5]undecanone and 5150 g ethanola—
mine in 47 L ethanol is heated to 75-80°C for 17 h. After the suspension has been cooled
to 20°C the precipitate is filtered off and washed with 15 L ethanol. After drying at 60°C in
vacuo, 3776 g of product is obtained as the mono—ethanol solvate.
Mass spectrum (ESP): m/z = 486 [M+H]+
1H NMR (400 MHz, DMSO): 9.60 (1H, s); 8.37 (1H, s); 7.82 (1H, s); 7.44-7.55 (2H, m),
7.37 (1H, s); 7.28 (1H, t); 7.22 (1H, s); 4.63-4.69 (1H, m); 4.33 (1H, t); 3.96 (3H, s); 3.41-
3.49 (2H, m); 3.11-3.16 (2H, m); 2.82-2.87 (2H, m); 2.30 (1H, s); 2.14-2.23 (2H, m); 1.34-
1.97 (4H, m); 1.44-1.51 (2H, m); 1.06 (3H, t).
Example 11
(trans)[4—(3-chlorofluoro-phenylamino)methoxy-quinazolinyloxy]-1 ,4-diaza-
spiro[5.5]undecanone dimaleic acid compound
(I)
Process step M
A solution of 1680 g maleic acid in 7 L ethanol and 7 L water is added at 77°C to 3500 g
(trans)—9-[4-(3-chlorofluoro-phenylamino)methoxy-quinazolin-6—yloxy]-1 ,4-diaza-
.5]undecanone thanol solvate in 18 L of ethanol. The ng funnel is
rinsed with 3 L ethanol. The solution is inoculated with product at 66°C and after 5 min 35
L ethanol are added dropwise to the suspension. The suspension is cooled to 20° and
stirred for 1 h at this ature. Then it is cooled to 1°C and stirred for 16 h at this tem-
perature. The precipitate is filtered off and washed twice with 10 L ethanol. After drying at
60°C in vacuo, 4362 g of product is ed.
Mass spectrum (ESl+): m/z = 486 [M+H]+
1H NMR (400 MHz, DMSO): 8.50 (1H, s); 8.24 (1H, s); 7.93 (1H, s); 7.50—7.57 (2H, m),
7.29-7.35 (1H, m); 7.27 (1H, s); 6.15 (4H, s); 4.65-4.71 (1H, m); 3.98 (3H, s); 3.45-3.51
(2H, m); 3.39-3.44 (2H, m); 2.38—2.48 (2H, m); 2.06-2.15 (2H, m); 1.83-2.02 (4H, m).
Example 1 2
(trans)—9-(4-chIoromethoxy-quinazolinyloxy)(2,2,2-trifluoro—acetyl)-1 ,4-diaza-
spiro[5.5]undecanone
(12)
Process step I+N
19.6 g N-chlorosuccinimide in 240 mL acetonitrile are added at 60°C within two s to
a mixture of 60 g tert-butyl (trans)—9-(4-hydroxymethoxy-quinazolinyloxy)—5-oxo
—trifluoro-acetyl)—1,4-diaza-spiro[5.5]undecanecarboxylate and 37.5 g triphenyl-
phosphine in 300 mL dioxane. The e is heated to 80-90°C for 100 min. After 20 min
at 50-60°C, 84 mL of 4 M hydrochloric acid in dioxane are added to the mixture and the
mixture is stirred for 3 h at 50-85°C. After stirring for 17 h at ambient temperature the mix-
ture is cooled to 5°C and the precipitate is filtered off. The filter cake is washed with
a 1:1
mixture of dioxane/acetonitrile and with tert-butylmethylether. After drying at 50°C 40 g of
product is obtained.
Mass spectrum (ESP): m/z = 473 [M+H]+
Collection of data
The following equipment and test ions are used to collect the data appended hereto.
X-ray powder diffractometer
STOE Stadi P X-ray powder diffractometer with a location-sensitive detector in transmis-
sion mode with a curved germanium (111) primary monochromator; wavelength used:
Cqu with 7» = 1.540598 A; ion of the X—ray tube: 40 kV, 40 mA; 2 9 range: 3-40°.
Thermoanalysis eguipment
A DSC 822 made by r Toledo is used. The following measuring parameters
used: heating rate: 10 K/min; type of crucible: perforated aluminium crucible; atmosphere:
N2, 80 m|/min flux; typical weights: 3-10 mg.
A TGA/SDTA 851 made by Mettler Toledo which is coupled to a Nicolet FT-lR 4700 spec-
trometer (for analysing the volatile fractions) is used. The following measuring parameters
are used: heating rate: 10 K/min; type of crucible: open aluminium oxide le; atmos-
phere: N2, 20 ml/min flux; typical s: 15-25 mg.
The melting point of compound (I) can be inferred from the DSC/TG schemes in Figure 2
1O appended hereto.
Eguipment for water sorption tests
A DVS-1 made by Surface Measurement Systems (= SMS) is used to test the hygroscopic
characteristics: the following humidity profiles are used: 10 — 90 % r.h. in 1O % steps, re-
cording both a sorption and a desorption profile, l s: 10 — 20 mg
The corresponding ms (kinetic and isothermic plot) of the different forms are shown
in Figures 3a) and b).
Biological Test
The biological properties of compound (I) are igated as follows, for example:
The inhibition of the EGF-R—mediated signal transmission can be demonstrated
e.g. with
cells which express human EGF—R and whose survival and proliferation depend on stimu-
lation by EGF or TGF-alpha. A murine haematopoietic cell line is genetically modified so
as to express functional human EGF-R. The proliferation of this cell line can therefore be
stimulated by EGF.
The test is carried out as follows:
The cells are cultivated in RPMl/1640 medium. The proliferation is ated with 20
ng/ml of human EGF (Promega). To investigate the inhibitory activity of the compounds
according to the invention these compounds are dissolved in 100% dimethylsulphoxide
(DMSO) and added to the cultures in various dilutions, the maximum DMSO concentration
being 1%. The cultures are incubated for 48 hours at 37°C.
In order to determine the inhibitory activity of nd (I) according to the invention the
relative cell number is measured in OD. units using the Cell Titer 96TM AQueous Non-
Radioactive Cell Proliferation Assay (Promega). The relative cell number is calculated as
a percentage of the control and the concentration of active substance which inhibits the
proliferation of the cells by 50% (IC50) is derived therefrom.
1O Table 2
Compound tion of the EGFR-dependent
proliferation
lcso [NM]
Indications
As has been found, the compound of formula (I) is characterised by its versatility in the
therapeutic field. Particular mention should be made of the possible applications for which
the nd of formula (I) according to the invention is preferably used on the basis of
its ceutical efficacy as a ne inhibitor.
The compound of general formula (I) according to the invention thus inhibits signal trans-
n by tyrosine kinases, as trated by the example of the human EGF receptor,
and is therefore useful for treating pathophysiological processes caused by unction
of tyrosine kinases. These are e.g. benign or malignant tumours, particularly tumours of
lial and neuroepithelial origin, metastasisation and the abnormal eration of vas—
cular endothelial cells (neoangiogenesis).
The compound (I) according to the invention is also useful for preventing and treating dis-
eases of the airways and lungs which are accompanied by increased or altered production
of mucus caused by stimulation of tyrosine kinases, e.g. in inflammatory diseases of the
airways such as chronic bronchitis, chronic obstructive bronchitis, asthma, bronchiectasis,
allergic or non-allergic rhinitis or sinusitis, cystic fibrosis, a1—antitrypsin deficiency, or
coughs, pulmonary emphysema, pulmonary fibrosis and hyperreactive airways.
The compound (I) is also suitable for treating diseases of the gastrointestinal tract and bile
duct and gall bladder which are associated with disrupted activity of the tyrosine kinases,
such as may be found e.g. in chronic inflammatory changes such as cholecystitis, Crohn’s
disease, tive colitis, and ulcers in the gastrointestinal tract or such as may occur in
diseases of the gastrointestinal tract which are associated with increased secretions, such
as Ménétrier’s disease, secreting adenomas and protein loss syndrome.
In addition, the compound (I) may be used to treat other diseases caused by abnormal
function of tyrosine kinases, such as e.g. epidermal roliferation (psoriasis), benign
prostatic hyperplasia (BPH), inflammatory ses, diseases of the immune system,
hyperproliferation of haematopoietic cells, the treatment of nasal , etc.
Combinations
The compound of formula (I) may be used on its own or in combination with other active
substances. These combinations may be administered either simultaneously or sequen-
tially. ally the compound of formula (I) may also be used in combination with W,
wherein W denotes a pharmacologically active substance and is selected (for example)
from among betamimetics, anticholinergics, corticosteroids, PDE4-inhibitors, LTD4-
receptor (CysLT1, CysLT2, ) antagonists, LTB4-receptor (BLT1, BLT2) antago-
nists, tors of MAP kinases such as for example p38, ERK1, ERK2, JNK1, JNK2,
JNK3 or SAP, bradykinin (BK1, BK2) receptor nists, endothelin receptor antago-
nists, CXCR1 and/ or CXCR2 receptor antagonists, and anti-tussive substances.
In addition, double or triple combinations Of W may be combined with the nds of
formula (I). Examples of combinations of W with the compound of formula (I) might be:
o W denotes a betamimetic, ed with an olinergic, corticosteroid, PDE4-
or, EGFR-inhibitor or LTD4-receptor antagonist,
o W denotes an anticholinergic, combined with a metic, corticosteroid, PDE4-
inhibitor, EGFR-inhibitor or LTD4—receptor antagonist,
o W denotes a corticosteroid, combined with a PDE4-inhibitor, EGFR-inhibitor or LTD4-
receptor antagonist
o W denotes a PDE4-inhibitor, combined with an EGFR—inhibitor or LTD4—receptor an-
tagonist
o W denotes an EGFR—inhibitor, combined with an anticholinergic.
Examples of betamimetics which may be used here preferably include compounds which
are selected from among arformoterol, carmoterol, formoterol, indacaterol, salmeterol, al-
l, bambuterol, erol, erol, carbuterol, clenbuterol, fenoterol, hexoprenalin,
ibuterol, isoetharin, isoprenalin, levosalbutamol, mabuterol, meluadrin, metaproterenol,
milveterol, orciprenalin, pirbuterol, procaterol, reproterol, rol, ritodrin, salmefamol,
soterenol, sulphonterol, terbutalin, id, tolubuterol, zinterol and
6—hydroxy-8—{1-hydroxy[2-(4-methoxy-phenyl)—1 ,1 -dimethyl-ethylamino]-ethyI}-4H-
benzo[1 ,4]oxazin-3—one, 8—{2-[2-(2,4-difluoro-phenyl)-1,1-dimethyl-ethy|amino]hydroxy-
ethyl}—6-hydroxy-4H-benzo[1 ,4]oxazinone, 8—{2-[2-(3,5-difluoro-phenyl)-1 ,1 -dimethyl-
mino]hydroxy-ethy|}hydroxy-4H-benzo[1 ,4]oxazinone, 8—{2-[2-(4-ethoxy-
pheny|)-1 ,1 -dimethyl-ethylamino]-1 -hyd roxy-ethyl}-6—hydroxy-4H-benzo[1 ,4]oxazinone,
8—{2-[2-(4—fluoro-phenyl)-1 ,1 -dimethyl-ethylamino]-1—hydroxy-ethy|}hydroxy—4H-
benzo[1 ,4]oxazinone, N-(5-{2-[3—(4,4-diethyIoxo-4H-benzo[d][1 ,3]oxazinyl)-1 ,1-
dimethyl-propylamino]—1-hydroxy-ethyI}hydroxy-phenyl)-methanesuIphonamide, N-(5-
{2-[3—(4,4-diethyl—6—fluorooxo-4H-benzo[d][1,3]oxaziny|)-1,1-dimethyI-propylamino]-1—
hydroxy-ethy|}hydroxy-phenyl)—methanesuIphonamide, N-(5-{2—[3-(4,4-diethyI—6-
methoxyoxo-4H-benzo[d][1 ,3]oxazinyl)-1 ,1-dimethyI-propylamino]hydroxy-ethyl}-
2-hydroxy-pheny|)-methanesu|phonamide, N-(5-{2-[1,1-dimethyI(2-oxo-4,4-dipropyI-4H-
benzo[d][1 ,3]oxaziny|)-propylamino]hydroxy-ethy|}hydroxy-phenyl)-
methanesulphonamide, 8-{2-[1,1-dimethyl(2-oxo-2,3-dihydro-benzimidazol-1—yl)—
amino]—1-hydroxy-ethyI}hydroxy-4H-benzo[1 ,4]oxazinone, 8—{2-[1 ,1 -dimethyl-
3-(6—methyloxo-2,3-dihydro-benzimidazoIy|)-propylamino]hydroxy-ethyl}-6—
hydroxy-4H-benzo[1 ,4]oxazinone, 8—{2-[1 ,1 hyl(2-oxotrifluoromethyl-2,3-
dihydro-benzimidazoIyl)-propylamino]hydroxy-ethyl}hydroxy-4H-benzo[1 ,4]oxazin-
3-one, 8-{2-[1 ,1 —dimethyl(3-methyloxo-2,3-dihyd ro-benzimidazol-1 ropy|amino]-
1-hydroxy-ethyl}—6—hydroxy-4H-benzo[1 ,4]oxazinone, N-[2-hydroxy((1R)—1-hydroxy-
2-{2-[4-(2-hydroxy—2-phenyl—ethylamino)-phenyl]-ethylamino}-ethyl)—phenyl]-formamide, 8-
hydroxy—5-((1 R)—1-hydroxy{2-[4-(6—methoxy-biphenyIylamino)-phenyl]-ethylamino}-
ethy|)-1H-quinolinone, 8—hydroxy[(1R)—1-hydroxy(6—phenethylamino-hexylamino)-
ethyl]-1H-quinolinone, 5-[(1R)(2-{4-[4-(2-aminomethy|-propoxy)—pheny|amino]-
}-ethy|amino)hydroxy-ethyI]hydroxy—1 H-quinolinone, [3-(4-{6-[(2R)-2—
hydroxy(4-hydroxyhydroxymethyl-phenyl)-ethylamino]—hexy|oxy}—butyl)methyl-
]-urea, 4-((1 R){6-[2-(2,6-dichIoro-benzyloxy)—ethoxy]-hexylamino}hydroxy-
ethy|)—2-hydroxymethyI-phenol, 3-(4-{6-[(2R)hydroxy(4-hydroxyhydroxymethyl-
phenyI)—ethylamino]-hexyloxy}-buty|)-benzenesuIphonamide, 3-(3-{7-[(2R)hydroxy(4-
hydroxyhydroxymethyI-phenyl)—ethy|amino]-heptyloxy}-propy|)-benzenesu|phonamide,
4-((1 R){6-[4-(3-cyclopentanesulphonyI-phenyl)-butoxy]-hexylamino}hydroxy—ethyl)
hydroxymethyI-phenol, NadamantanyI{3-[(2R)—2-({(2R)—2-hydroxy[4-hydroxy—3-
(hydroxymethyl)phenyl]ethy|}amino)propy|]phenyl}acetamide, (1 R){2-[6-(2,2-difluoro—2-
phenyI-ethoxy)—hexy|amino]hydroxy-ethyI}hydroxy-1 H-quinolin-Z-one, (R,S)(2-{[6-
(2,2-difluoro-4—phenylbutoxy)hexyl]amino}hydroxy—ethyI)—2-(hydroxymethyl)phenol,
(R,S)—4-(2-{[6-(2,2-difluoro-2—phenylethoxy)hexyl]aminc}-1—hydroxy—ethyI)—2-
(hydroxymethyl)pheno|, (R,S)—4—(2-{[4,4—difluoro(4-phenylbutoxy)hexyl]amino}-1 -
hydroxy—ethyI) (hydroxymethy|)pheno|, (R,S)—4-(2-{[6-(4,4-diquoro
phenylbutoxy)hexyl]amino}hydroxy-ethyl)(hydroxymethyl)phenol, (R,S)—5-(2-{[6-(2,2-
difluorophenylethoxy)hexyl]amino}hydroxy-ethyl)—8— hydroxyquinolin-2(1 H)-one,
[2-({6-[2,2-difluoro(3-methylphenyl)ethoxy]hexy|}amino)—1-hydroxyethyI]
(hydroxymethyl)phenol, 4—(1R)—2-{[6-(2,2-difluorophenylethoxy)hexyl]amino}
hydroxyethyl)-2—(hydroxymethyl)phenol, (R,S)—2-(hydroxymethyl)—4-(1-hydroxy{[4,4,5|5-
tetrafluoro—6-(3-phenylpropoxy)hexyl]amino}ethyl)phenol, (R,S)-[5-(2-{[6-(2,2-difluoro—2-
phenylethoxy)hexyl]amino}hydroxy—ethyI) hydroxyphenyl]formamide, (R,S)—4-[2-({6-
[2-(3-bromophenyl)—2,2-difluoroethoxy]hexyl}amino)-1—hydroxyethy|]- 2-
(hydroxymethyl)phenol, (R, S)—N-[3-(1,1-difluoro{[6-({2—hydroxy[4-hydroxy
xymethyl)phenyl]ethyl}amino)hexy|]oxy}ethy|)phenyI]-urea, 3-[3-(1 ,1—difluoro{[6-
({2-hydroxy—2-[4—hydroxy(hydroxymethyl) phenyl]ethyl}-
amino)hexyl]oxy}ethyl)phenyl]imidazolidin-2,4—dione, (R,S)—4—[2-({6-[2,2-difluoro—2-(3-
methoxyphenyl)ethoxy]hexy|}amino)—1-hydroxyethyI](hydroxymethyl)phenol, 5-((1 R)
,2-difluorophenylethoxy)hexyl]amino}hydroxyethyl)—8- hydroxyquinolin-2(1H)-
one, 4-((1 R)—2-{[4,4-difluoro—6—(4-phenylbutoxy)hexyl]amino}hydroxy—ethyl)—2-
(hydroxymethyl)phenol, (R,S)—4—(2-{[6-(3,3-difIuorophenylpropoxy)hexyl]amino}-1 -
hydroxy-ethyl)—2-(hydroxymethyl)phenol, (R,S)—(2-{[6—(2,2-difluorophenylethoxy)—4,4-
rohexy|]amino}hydroxyethy|)(hydroxymethyl)phenol, (R,S)—4—(2-{[6-(2,2-
difluorophenylpropoxy)hexyl]amino}hydroxy ethyI)-2— (hydroxymethyl)phenol, 3-[2-(3-
chloro-phenyl)—ethoxy]—N-(2-diethylamino—ethyl)-N-{2-[2-(4-hydroxy—2-oxo—2,3-dihyd ro-
benzothiazol-7—yl)—ethylamino]-ethy|}-propionamide, N-(2-diethylamino-ethyl)-N-{2-[2—(4—
hydroxy-2—oxo-2,3-dihydro-benzothiazolyI)-ethylamino]-ethyl}(2-naphthalenyl-
ethoxy)—propionamide
7-[2-(2-{3-[2-(2-chloro—phenyl)-ethylamino]-propylsulphanyl}—ethylamino)hydroxy-ethyl]-
4-hydroxy-3H-benzothiazole-2—one,
optionally in the form of the racemates, enantiomers, diastereomers and ally in the
form of the pharmacologically acceptable acid addition salts, solvates or hydrates thereof.
Preferably, according to the invention, the acid addition salts of the betamimetics are se-
lected from among hydrochloride, hydrobromide, dide, hydrosulphate, hydrophos—
phate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate,
hydrofumarate, artrate, alate, hydrosuccinate, hydrobenzoate and hydro-p-
toluenesulphonate.
Examples of anticholinergics which may be used here preferably include compounds
which are selected from among: tiotropium salts, preferably the bromide salt, oxitropium
salts, preferably the bromide salt, flutropium salts, preferably the e salt, ipratropium
salts, preferably the bromide salt, aclidinium salts, preferably the bromide salt, yr-
ronium salts, preferably the bromide salt, trospium salts, preferably the chloride salt,
tolterodine, (3R)phenethy|(9H-xanthencarbonyloxy)—1-azoniabicyclo[2,2,2]octane-
salts. In the above-mentioned salts the cations are the pharmacologically active constitu-
ents. As X' anions the mentioned salts may preferably contain chloride, e,
iodide, sulphate, phosphate, methanesulphonate, e, maleate, acetate, e, fu-
marate, tartrate, oxalate, succinate, benzoate or p-toluenesulphonate, while chloride,
bromide, iodide, sulphate, methanesulphonate or p-toluenesulphonate are preferred as
counter-ions. Of all the salts the chlorides, bromides, iodides and methanesulphonates
are particularly preferred.
Other specified compounds are: tropenol 2,2—diphenylpropionate methobromide,
scopine 2,2-diphenylpropionate romide, scopine 2—fluoro-2,2-diphenylacetate
methobromide, ol 2-fluoro-2,2—diphenylacetate methobromide, tropenol 3,3',4,4'-
tetrafluorobenzilate methobromide, scopine 3,3',4,4'-tetrafluorobenzilate methobromide,
tropenol 4,4'-difluorobenzilate methobromide, scopine 4,4'-difluorobenzilate methobro-
mide, tropenol 3,3'—difluorobenzilate methobromide, scopine 3,3'— difluorobenzilate
methobromide; tropenol 9-hydroxy—fluorene-Q-carboxylate methobromide, tropenol 9-
fluoro-fluorene-Q—carboxylate methobromide, scopine oxy-fluorene carbokylate
methobromide, scopine 9—fluoro-fluorene—9—carboxylate methobromide; tropenol 9-methyl-
ne—9— carboxylate methobromide, scopine 9—methyl—fluorene—9— carboxylate metho-
bromide, cyclopropyltropine benzilate romide, cyclopropyltropine 2,2-
diphenylpropionate methobromide, cyclopropyltropine 9—hydroxy-xanthenecarboxylate
methobromide, cyclopropyltropine 9-methyl-fluorene—9-carboxylate methobromide, cyclo-
propyltropine 9-methyl-xanthene-9—carboxylate romide, cyclopropyltropine 9-
hydroxy-fluorenecarboxylate methobromide, cyclopropyltropine methyl 4,4'-
difluorobenzilate romide, tropenol oxy—xanthenecarboxylate methobro-
mide, scopine 9-hydroxy-xanthene—9-carboxylate methobromide, tropenol 9—methyl—
ne—9—carboxylate -methobromide, e 9-methyl-xanthene—9-carboxylate -
methobromide, tropenol l-xanthene—9-carboxylate methobromide, tropenol 9-
romethyI-xanthenecarboxylate methobromide, scopine 9-hydroxymethyl-
xanthene—9—carboxylate methobromide. The above-mentioned compounds may also be
used as salts within the scope of the present invention, while instead of the methobro-
mide, the metho-X salts may be used wherein X may have the meanings given hereinbe-
fore for X'.
Compounds which may be used as osteroids are preferably those selected from
among: ethasone, betamethasone, budesonide, butixocort, ciclesonide, de-
ort, dexamethasone, etiprednol, flunisolide, fluticasone, |oteprednol, mometasone,
prednisolone, prednisone, rofleponide, triamcinolone, tipredane and pregna-1,4-diene—
3.20-dione, 6-fluorohydroxy-16,17-[(1—methylethylidene)bis(oxy)][[4-
[(nitrooxy)methy|]benzoyl]oxy]-, (6-alpha,11—beta,16-alpha)— (9Cl) (NCX-1024), 16,17-
butylidenedioxy-6,9-dif|uoro-1 1-hydroxy(methylthio)androst-4—enone (RPR-
106541 ), (S)—fluoromethyl 6,9-difluoro[(2-furanylcarbonyl)oxy]-1 1-hydroxymethyl-
3-oxo—androsta—1,4-diene—17-carbothionate, (S)-(2-oxo-tetrahydro-furan-3S-yl) 6,9-
difluoro—1 1-hydroxymethyloxo—1 7—propionyloxy—androsta-1 ,4-dien-1 7-carbothionate,
cyanomethyl 6-alpha,9-alpha-difluoro-1 1-beta-hydroxy-16alpha-methyloxo—17alpha—
(2,2,3,3-tetramethylcyclopropylcarbonyl)oxy-and rosta-1 ,4-diene-1 7beta-carboxylate,
optionally in the form of the racemates, enantiomers or reomers thereof and option-
ally in the form of the salts and derivatives thereof, the solvates and/or hydrates thereof.
Any nce to steroids includes a reference to any salts or derivatives, hydrates or sol—
vates thereof which may exist. Examples of possible salts and derivatives of the steroids
may be: alkali metal salts, such as for example sodium or potassium salts, sulphobenzo-
ates, phosphates, isonicotinates, acetates, dichloroacetates, propionates, dihydrogen
phosphates, palmitates, pivalates or furoates.
PDE4-inhibitors which may be used are preferably compounds selected from among en-
profyllin, theophyllin, roflumilast, ariflo (cilomilast), tofimilast, ntrin, lirimilast, apre-
, arofyllin, atizoram, oglemilast, tetomilast, and
-[(N-(2,5-dichloro—3—pyridinyl)-carboxamide]methoxy—quinoline (D-4418), N-(3,5-
dichiorooxidopyridinyl)-carboxamide]methoxy(trif|uoromethyl)—quinoline (D—
4396 (Sch-351591)), -dichIoropyrid-4—y|)-[1-(4-f|uorobenzy|)-5,-hydroxy-indo|
y|]g|yoxy|ic acid amide (AWD281 (GW-842470)), 9-[(2-f|uorophenyl)methyI]-N-methyl-
2—(trifluoromethyl)—9H-purinamine (NOS-613), 4-[(2R)[3-(cyc|opentyloxy)—4-
methoxyphenyl]phenylethyi]-pyridine (GDP-840), N-[(3R)-3,4,6,7-tetrahydromethyI
oxopheny|pyrrolo[3,2,1-jk][1,4]benzodiazepinyI]pyridinecarboxamide (PD-
168787), 4-[6,7-diethoxy-2,3—bis(hydroxymethy|)—1-naphthaienyl]—1-(2-methoxyethyl)-
2(1H)—pyridinone (T-440), 6,7-diethoxy—2,3-bis(hydroxymethyI)naphthalenyl]
pyridiny|]—4-(3-pyridinyI)-1(2H)-phthalazinone (T-2585), (3-(3-cyclopenyioxy
ybenzyl)ethy|aminoisopropyi-3H—purine (V-1 1294A), beta-[3—(cyciopentyloxy)—
oxyphenyl]—1,3-dihydro-1,3-dioxo-2H—isoindole-2—propanamide (CDC-801), imi-
dazo[1,5—a]pyrido[3,2-e]pyrazin-6(5H)—one, 9-ethylmethoxy-7—methylpropyl- (D-
22888), 5-[3-(cyclopentyloxy)—4-methoxyphenyl]—3-[(3-methy|phenyl)methyl], (3S,58)—2-
piperidinone (HT-0712), 4-[1-[3,4-bis(dif!uoromethoxy)phenyl]—2-(3-methyl-1—oxido—4-
pyridinyl)ethyi]—alpha,alpha—bis(trif|uoromethyl)-benzenemethano| (L-826141), N-(3,5-
dichlorooxo-pyridinyI)difluoromethoxy—3-cyclopropylmethoxybenzamide, (-)p-
,10bS*)—9-ethoxy-1,2,3,4,4a,10b-hexahydro-8—methoxy—2-
methylbenzo[s][1,6]naphthyridin-6—yI]-N,N-diisopropylbenzamide, (R)-(+)(4-
bromobenzyi)[(3-cyciopentyloxy)—4-methoxyphenyI]pyrrolidone, 3-(cyclopentyloxy
methoxyphenyl)(4-N'-[Ncyano-S-methyI-isothioureido]benzyl)—2-pyrrolidone, cis[4-
cyano(3-cyclopentyloxymethoxyphenyl)cyclohexanecarboxy|ic acid], 2-
ethoxy—4-cyano(3-cyclopropylmethoxy-4—d ifluoromethoxyphenyl)cyclohexan-1 -
one, cis[4-cyano(3-cyclopropylmethoxydifluoromethoxyphenyl)cyclohexano|], (R)-
(+)-ethyl[4-(3-cyclopentyloxy—4-methoxyphenyl)pyrrolidinylidene]acetate, (S)-(-)—ethy|[4-
(3-cyclopentyloxy—4-methoxyphenyl)pyrroiidinylidene]acetate, 9-cyclopentyI-5,6-
dihydroethyl(2-thienyl)-9H-pyrazolo[3,4-c]-1,2,4—triazolo[4,3-a]pyridine, 9-
cyclopentyl-5,6-dihyd roethyI-3—(tert-butyl)-9H-pyrazo|o[3,4-c]-1 ,2,4—triazo|o[4,3-
a]pyridine,
optionally in the form of the racemates, enantiomers, diastereomers thereof and optionally
in the form of the pharmacologically acceptable acid addition salts, solvates or hydrates
thereof. According to the invention the preferred acid addition salts are ed from
among hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydro-
methanesulphonate, hydronitrate, hydromaleate, cetate, hydrocitrate, hydrofu-
, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-
toluenesulphonate.
LTB4-receptor antagonists used here are preferably compounds selected from among for
example ant (=ethyl [[4-[[3-[[4-[1-(4—hydroxypheny|)
methylethyl]phenoxy]methy|]phenyl]methoxy]pheny|]iminomethyl]-carbamate), optionally
in the form of the tes, enantiomers, diastereomers thereof and optionally in the
form of the pharmacologically acceptable acid addition salts, solvates, prodrugs or hy-
drates thereof. According to the invention the red acid addition salts are selected
from among hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate,
hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydro-
fumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-
toluenesulphonate.
LTD4-receptor antagonists used here are preferably compounds selected from among
montelukast, pranlukast, zafirlukast, and (E)—8-[2—[4-[4-(4-
fluorophenyl)butoxy]phenyl]ethenyI]—2-(1 H-tetrazoI—5-yl)-4Hbenzopyranone (MEN-
91507), cetyl[3-(4—acetyIhydroxy—2-propylphenylthio)propoxy]
propylphenoxy]butyric acid (MN-001), )—(3-(2-(6,7-difluoro
quinolinyl)ethenyl)phenyl)—3-(2-(2-hydroxypropyl)phenyl)thio)methy|cyc|opropaneacetic
acid, 1-(((1 ( -(2—(2,3-dichlorothieno[3,2-b]pyridinyl )-( E)-ethenyl)phenyl)(2-(1 -
hydroxy-1—methylethyl)pheny|)propyl)thio)methy|) cyclopropaneacetic acid, -(4-tert-
butyl—2-thiazolyl)—5-benzofurany|]oxymethyl]phenyl]acetic acid optionally in the form of the
tes, enantiomers, diastereomers thereof and optionally in the form of the pharma-
cologically acceptable acid addition salts, solvates or es thereof. According to the
invention the preferred acid addition salts are selected from
among hloride, hydro-
bromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydroni-
trate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydrox-
alate, hydrosuccinate, hydrobenzoate and p-toluenesulphonate.
By salts or derivatives which the LTD4—receptor antagonists are optionally capable of
forming are meant, for example: alkali metal salts, such as for example sodium or potas-
sium salts, alkaline earth metal salts, sulphobenzoates, phosphates, otinates, ace-
tates, propionates, dihydrogen phosphates, palmitates, pivalates or furoates.
MAP Kinase inhibitors used are preferably compounds selected from among:
bentamapimod (AS-602801), doramapimod 796), 5-carbamoylindole (SD-169), 6-
[(aminocarbonyl)(2,6-dif|uoropheny|)amino](2,4-difluorophenyl)pyridinecarboxamide
(VX—702), a|pha-[2-[[2-(3-pyridiny|)ethyl]amino]pyrimidiny|]benzothiazoleacetonitrile
(AS-601245), 9,12—epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4—i][1.6]benzodiazocine—
-carboxylic acid (CEP-1347), 4-[3-(4-chlorophenyl)—5-(1-methyl-4—piperidinyl)-1 H-
pyrazoley|]-pyrimidine (SC-409),
optionally in the form of the racemates, enantiomers, diastereomers thereof and optionally
in the form of the pharmacologically acceptable acid addition salts, prodrugs, solvates or
hydrates thereof.
Bradykinin receptor antagonists that may be used are preferably compounds selected
from among icatibant and 1-piperazinepentanaminium, delta-amino[[4—[[[2,4-dichloro
[[(2,4-dimethyl-8—quinoliny|)oxy]methyl]pheny|]su|phonyl]amino]tetrahydro-2H-pyran
bony|]-N,N,N-trimethyl-£-oxo, chloride, hloride (1 :1 :1), (deltaS)- (MEN-16132),
optionally in the form of the racemates, omers and diastereomers thereof and op-
ly in the form of the cologically acceptable acid on salts, prodrugs, sol-
vates or hydrates thereof.
Endothelin antagonists that may be used are preferably compounds ed from
among
actelion-1, ambrisentan, sitaxsentan, N-(2-acetyl-4,6-dimethylphenyl)—3-[[(4-ch|oro
methylisoxazolyl)amino]sulphonyl]thiophenecarboxamide (TBC-3214) and bosentan,
ally in the form of the racemates, enantiomers and diastereomers thereof and op-
tionally in the form of the pharmacologically acceptable acid addition salts, prodrugs, sol-
vates or hydrates thereof.
Antitussive substances that may be used are preferably compounds selected from
among
hydrocodone, caramiphen, carbetapentane and dextramethorphan, optionally in the form
of the tes, enantiomers and diastereomers thereof and optionally in the form of the
pharmacologically acceptable acid on salts, prodrugs, solvates or hydrates thereof.
Substances of preferred CXCR1 and /or CXCR2 receptor antagonists that may be used
are preferably compounds such as e.g. 3-[[3-[(dimethylamino)carbony|]
hydroxyphenyl]amino]—4—[[(R)(5-methylfurany|)propy|]amino]cyc|obutene-1,2-dione
1O (SCH-527123),
optionally in the form of the racemates, enantiomers and diastereomers thereof and op-
tionally in the form of the pharmacologically acceptable acid addition salts, prodrugs, sol-
vates or hydrates thereof.
it is preferable, according to the invention, to use the acid addition salts of the above—
mentioned metics, anticholinergics, corticosteroids, PDE4 inhibitors, LTB4(BLT1,
BLT2) receptor nists, LTD4 (CysLT1, CysLT2, CysLT3) or antagonists, in-
hibitors of MAP kinases such as for example p38, ERK1, ERK2, JNK‘l, JNK2, JNK3 or
SAP, bradykinin receptor antagonists, endothelin receptor antagonists, antitussive sub-
stances, CXCR1 and / or CXCR2 receptor antagonists also ed from among hydro-
chloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesul-
e, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotar-
trate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate.
Pharmaceutical compositions
The compound according to the invention may be administered by oral, transdermal, inha-
lative, eral or sublingual route. The compound according to the invention is present
as an active ingredient in conventional preparations, for example in itions consist-
ing ially of an inert pharmaceutical carrier and an effective dose of the active sub-
stance, such as for example tablets, coated tablets, capsules, wafers, powders, solutions,
suspensions, emulsions, syrups, suppositories, transdermal systems etc. An effective
dose of the compound according to the invention for oral administration is between 0.1
and 5000, ably n 1 and 500, particularly preferably between 5-300 mg/dose,
when administered by intravenous, subcutaneous or uscular route between 0.001
and 50, preferably between 0.1 and 10 mg/dose. For Inhalation,
according to the invention
suitable solutions are those that contain 0.01 to 1.0, preferably 0.1 to 0.5 % of active sub-
stance. For inhalative administration the use of powders, ethanolic or
aqueous solutions is
red. It is also possible to use the compound according to the invention as an infu-
sion solution, preferably in a physiological saline solution or nutrient solution.
The compound according to the invention
may be used on its own or in conjunction with
other active substances according to the invention, optionally also in conjunction with
other pharmacologically active substances. Suitable formulations include, for example,
tablets, capsules, suppositories, solutions, syrups, emulsions or dispersible powders.
Corresponding s may be obtained for example by mixing the active substance(s)
with known excipients, for e inert diluents, such as calcium carbonate, calcium
phosphate or lactose, egrants such as maize starch or alginic acid, binders such as
starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delay-
ing release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl
acetate. The tablets may also comprise several layers.
Coated tablets may be prepared accordingly by coating cores produced ously to
the tablets with substances normally used for tablet coatings, for example collidone
shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed e or
pre-
vent atibilities the core may also t of a number of . Similarly the tablet
coating may consist of a number of layers to achieve delayed e, possibly using the
excipients mentioned above for the tablets.
Syrups containing the active substances or ations thereof according to the inven-
tion may additionally contain a sweetener such as saccharine, cyclamate, glycerol
sugar and a flavour enhancer, e.g. a flavouring such as vanillin or orange t. They
may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cel—
lulose, wetting agents such as, for e, condensation ts of fatty alcohols with
ethylene oxide, or preservatives such as p-hydroxybenzoates.
Solutions for injection are prepared in the usual way, e.g. with the addition of
preserva-
tives such as oxybenzoates, or stabilisers such as alkali metal salts of ethylenedia-
mine tetraacetic acid, and transferred into injection vials or ampoules.
Capsules containing one or more active substances or combinations of active substances
may for e be ed by mixing the active substances with inert carriers such as
e or sorbitol and packing them into gelatine capsules.
Suitable suppositories may be made for example by mixing with carriers provided for this
purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.
For pharmaceutical use the compound according to the invention is generally used for
warm-blooded vertebrates, particularly , in doses of 0.01-100 mg/kg of body
weight, preferably 0.1-15 mg/kg. For administration it may be ated for example with
one or more tional inert carriers and/or diluents, e.g. with corn starch, lactose, glu-
cose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tar-
taric acid, water, water/ethanol, water/glycerol, sorbitol, water/polyethylene glycol,
propylene glycol, stearyl alcohol, carboxymethylcellulose or fatty substances such as hard
fat or suitable mixtures thereof to produce conventional galenic preparations such as plain
or coated tablets, capsules, powders, suspensions, solutions, sprays or suppositories.
The Examples which follow rate the present invention without restricting its scope:
WO 04206 38 2012/051298
Examples of pharmaceutical ations
A) Coated tablets containing 75 mg of active substance
Composition:
1 tablet core contains:
active substance 75.0 mg
calcium phosphate 93.0 mg
corn starch 35.5 mg
polyvinylpyrrolidone 10.0 mg
hydroxypropylmethylcellulose 15.0 mg
magnesium stearate 1.5 mg
230.0 mg
Preparation:
The active substance is mixed with m phosphate, corn starch, polyvinyl—pyrrolidone,
hydroxypropylmethylcellulose and half the specified amount of magnesium te.
Blanks 13 mm in diameter are produced in a tablet-making machine and these are then
rubbed through a screen with a mesh size of 1.5 mm using a suitable machine and mixed
with the rest of the magnesium stearate. This granulate is compressed in a tablet-making
machine to form tablets of the desired shape.
Weight of core: 230 mg
die: 9 mm, convex
The tablet cores thus produced are coated with a film consisting essentially of hydroxypro-
pylmethylcellulose. The finished film-coated tablets are polished with beeswax.
Weight of coated : 245 mg.
B) Tablets containing 100 mg of active substance
Composition:
1 tablet contains:
active substance 100.0 mg
lactose 80.0 mg
corn starch 34.0 mg
polyvinylpyrrolidone 4.0 mg
magnesium stearate g.0_mg
Method of Preparation:
The active substance, lactose and starch are mixed together and uniformly moistened with
an aqueous solution of the polyvinylpyrrolidone. After the moist ition has been
ed (2.0 mm mesh size) and dried in a rack-type drier at 50°C it is screened again
(1.5 mm mesh size) and the lubricant is added. The finished mixture is compressed to
form tablets.
Weight of tablet: 220 mg
Diameter: 10 mm, biplanar, ed on both sides and notched on one side.
C) Tablets containing 150 mg of active substance
Composition:
1 tablet contains:
active substance 150.0 mg
powdered lactose 89.0 mg
corn starch 40.0 mg
colloidal silica 10.0 mg
polyvinylpyrrolidone 10.0 mg
magnesium stearate M
300.0 mg
Preparation:
The active substance mixed with lactose, corn starch and silica is moistened with a 20%
aqueous polyvinylpyrrolidone solution and passed through a screen with a mesh size of
1.5 mm. The granules, dried at 45°C, are passed through the same screen again and
mixed with the specified amount of magnesium te. Tablets are pressed from the
mixture.
Weight of tablet: 300 mg
die: 10 mm, flat
D) Hard gelatine capsules containing 150 mg of active substance
Composition:
1 capsule contains:
active substance 150.0 mg
corn starch (dried) approx. 180.0 mg
lactose (powdered) approx. 87.0 mg
magnesium te 3.0 mg
approx. 420.0 mg
Preparation:
The active substance is mixed with the excipients, passed through a screen with a mesh
size of 0.75 mm and neously mixed using a le apparatus. The finished mix-
ture is packed into size 1 hard gelatine capsules.
Capsule filling: approx. 320 mg
Capsule shell: size 1 hard gelatine capsule.
E) Suggositories containing 150 mg of active substance
Composition:
1 suppository contains:
active substance 150.0 mg
polyethyleneglycol 1500 550.0 mg
polyethyleneglycol 6000 460.0 mg
polyoxyethylene sorbitan monostearate 840.0 mg
0 mg
Preparation:
After the suppository mass has been melted the active substance is homogeneously dis-
tributed therein and the melt is poured into d moulds.
F) Suspension containing 50 mg of active nce
Composition:
100 ml of suspension contain:
active substance 1.00 g
carboxymethylcellulose-Na-salt 0.10 9
methyl p-hydroxybenzoate 0.05 g
propyl p-hydroxybenzoate 0.01 9
glucose 10.00 g
glycerol 5.00 g
70% ol solution 20.00 g
flavouring 0.30 g
dist. water ad 100 ml
Preparation:
The distilled water is heated to 70°C. The methyl and propyl p-hydroxybenzoates together
with the glycerol and sodium salt of carboxymethylcellulose are dissolved therein with stir-
ring. The solution is cooled to ambient temperature and the active substance is added and
homogeneously dispersed therein with stirring. After the sugar, the sorbitol on and
the flavouring have been added and dissolved, the suspension is evacuated with ng to
eliminate air.
ml of suspension contain 50 mg of active substance.
G) Ampoules containing 10 mg active substance
Composition:
active substance 10.0 mg
0.01 N hydrochloric acid q.s.
-distilled water ad 2.0 ml
Preparation:
The active nce is dissolved in the necessary amount of 0.01 N HCl, made isotonic
with common salt, filtered sterile and transferred into 2 ml ampoules.
H) Ampoules containing 50 mg of active substance
ition:
active substance 50.0 mg
0.01 N hydrochloric acid q.s.
double-distilled water ad 10.0 ml
Preparation:
The active substance is dissolved in the necessary amount of 0.01 N HCl, made isotonic
with common salt, filtered sterile and transferred into 10 ml ampoules.
Appendix
Table 1: X-ray reflections to 30o 2 Ɵ inclusive intensities ardised) of
Compound (1)
(9797753_1):KZA
53_1):KZA
Claims (12)
1. lline compound of formula (I) Cl NH O O F O O N OH OH OH OH N OMe NH O O (I), optionally in the form of the tautomers thereof, 5 wherein reflections in the X-ray powder diagram occur at dhkl values of 7.11, 5.77, 4.69, 4.36, 4.15, 3.85 and 3.61 Å.
2. Crystalline compound according to claim 1 for use as a medicament.
3. Use of a crystalline compound according to claim 1 for the manufacture of the a ment for the ent of inflammatory or allergic diseases of the airways. 10
4. Process for the stereoselective preparation of the compound of formula(I) ing to claim 1, optionally in the form of the tautomers thereof: Cl NH O O F O O N OH OH OH OH N OMe NH O O (I), wherein the process comprises reaction steps (A) to (M), wherein (A) is the reaction of 1,4-cyclohexanedione-mono-ethyleneketal with 15 ethylenediamine and chloroform to form a compound of formula (1) (1), (9797753_1):KZA (B) is the reaction of a compound of formula (1) to form the compound of formula (2) O O x HCl HN (2), 5 (C) is the on of a compound of formula (2) with bases selected from among NaOtBu, KOtBu and NaOEt , , K2CO3, Li2CO3 and Na2CO3 to form the compound of formula (3) O O (D) is the reaction of a compound of formula (3) with the protective group reagent 10 di-tert-butyldicarbonate in ation with (4-(dimethylamino)-pyridine (DMAP) to form the compound of formula (4) O O O N O (E) is the reduction of a compound of formula (4) with NaBH4 or LiBH4 to form the 15 compound of formula (5) HO O O N O (F) is the reaction of a compound of formula (5) with trifluoroacetic anhydride to form a compound of formula (6) HO O O N O O N F F 20 (6) (10257817_1):KZA (G) is the reaction of a compound of formula (6) with a compound of formula (13) and with a reagent selected from among triphenylphosphine/ diisopropyl azodicarboxylate, triphenylphosphine/ diethyl azodicarboxylate and tributylphosphine/ azodicarbonyl)dipiperidine to form a compound of formula (7) N O 5 (13) O O O N O N O O N F F (7) (H) is the reaction of a nd of formula (7) in the presence of Pd/C or Pd(OH)2 to form a compound of formula (8a) or its tautomeric form (8b), O O O N O N O O N F F (8a) O O O N O N O O N F F 10 (8b) (10257817_1):KZA (I) is the chlorination of the compound of formula (8a) or (8b) with a reactant selected from among rosuccinimide/triphenylphosphane oxalyl chloride, l chloride, phosphorus oxychloride, phosphorus pentachloride, carbon tetrachloride/triphenylphosphane, dichlorotriphenylphosphorane and P,P-dichloro- 5 phenylphosphine oxide, to form a compound of formula (9) O O O N O N O O N (9) F F (J) + (K) is the reaction of the compound of formula (9) with 3-chlorofluoroaniline and the cleaving of a protective group to form a nd of formula (11) or (11A) Cl NH F O O N O O N F F 10 (11) Cl NH F O O N O O N F F x HCl (11A) or instead of steps (J+K) optionally steps (N+O) may be used, wherein (10257817_1):KZA (N+O) is the cleaving of a protective group of the compound of formula (9) to form the compound of formula (12) and subsequent reaction with 3-chlorofluoroaniline to form the compound of formula (11) or (11A) O O N O O N F F (12), 5 (L) is the ng of another protective group with a reagent selected from among ethanolamine, ammonia and Ba(OH) to form the compound of formula (II) Cl NH F O O N OMe (II) (M) is the reaction of the compound of formula (II) with two equivalents of maleic acid to form a compound of formula (I), optionally in the form of the tautomers thereof, Cl NH O O F O O N OH OH OH OH N OMe HN O O 10 (I), n process steps (A) to (M) take place successively in the sequence specified and Step (M) is followed by crystallization and isolation of the nd of Formula (I). (10257817_1):KZA
5. Process according to claim 4, wherein s steps (J+K) are replaced by steps (N+O), wherein (N+O) is the cleaving of a protective group of the compound of formula (9) to form the compound of formula (12) and subsequent reaction with 3-chlorofluoroaniline to form 5 the compound of formula (11) or (11A) according to claim 4 O O N O O N F F (12).
6. s for the selective preparation of a compound of formula (I), wherein the process consists of process steps as d in claim 4 (I), (J), (K), (L), and (M) or of process steps (I), (N), (O), (L) and (M), wherein the process steps (I) to (M) in 10 each case take place successively in the sequence specified.
7. Process for the stereoselective ation of a compound of formula (II), wherein the process consists of process steps as defined in claim 4 (I), (J), (K) and (L), or of process steps (I),(N), (O) and (L), wherein the process steps (I) to (L) in each case take place successively in the sequence specified. 15 8. Process for the chlorination of a compound of Formula (8a) or (8b) O O O N O N O O N F F (8a) O O O N O N O O N F F (8b) (10257817_1):KZA with a nt selected from among N-chlorosuccinimide/triphenylphosphane oxalyl chloride, thionyl chloride, phosphorus oxychloride, orus pentachloride, carbon tetrachloride/triphenylphosphane, dichlorotriphenylphosphorane and P,P-dichlorophenylphosphine oxide, to form a compound of formula (9) O O O N O N O O N (9) F F
5 .
9. Intermediate of formula (7) O O O N O N O O N F F (7) optionally in the form of the tautomers thereof.
10. Intermediate of formula (8a) or (8b), O O O N O N O O N F F 10 (8a) O O O N O N O O N F F (8b) optionally in the form of the tautomers thereof. (10257817_1):KZA
11. Intermediate of formula (9), O O O N O N O O N (9) F F optionally in the form of the tautomers thereof.
12. Intermediate of formula (11) or (11A), Cl NH F O O N O O N F F 5 (11) Cl NH F O O N O O N F F x HCl (11A) optionally in the form of the tautomers thereof. Boehringer Ingelheim International GmbH By the Attorneys for the Applicant 10 N & FERGUSON Per: (10257817_1):KZA
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11152895.6 | 2011-02-01 | ||
EP11152895 | 2011-02-01 | ||
PCT/EP2012/051298 WO2012104206A1 (en) | 2011-02-01 | 2012-01-27 | 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one dimaleate, use thereof as a drug, and production thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ613917A NZ613917A (en) | 2015-08-28 |
NZ613917B2 true NZ613917B2 (en) | 2015-12-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8906931B1 (en) | 9-[4-(3-chloro-2-fluoro-phenylamino-7-methoxy-quinazoline-6-yloxy]-1,4-diaza-spiro[5.5]undecane-5-one dimaleate, use thereof as a medicament and method for the production thereof | |
US9610284B2 (en) | 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor | |
CA2733159A1 (en) | Cyclohexyloxy-substituted heterocyclics, medicines containing these compounds and method for the production thereof | |
BG65890B1 (en) | Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof | |
PL214798B1 (en) | Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof | |
AU2006326157A1 (en) | Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof | |
JP4468305B2 (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and methods for their production | |
TW200408643A (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | |
CA2733153C (en) | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them | |
NZ613917B2 (en) | 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diazaspiro[5.5]undecan-5-one dimaleate, use thereof as a drug, and production thereof | |
EP2875020B1 (en) | Process for the preparation of a fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one | |
OA16485A (en) | 9-[4-(3-chlor-2-fluor-phenylamino)-7methoxy-quinazolin-6-yloxy]-1,4-diazaspiro[5.5]undecan-5-one dimaleate, use thereof as a drug, and production thereof. | |
US20120046284A1 (en) | Salts and hydrates of 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4--cyclohexan-1-yloxy)-7-methoxy-quinazoline, their use as a medicament and the preparation thereof | |
CN111518092B (en) | Rivaroxaban acetic acid solvate and preparation method thereof | |
TW201247653A (en) | 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy-quinazoline-6-yloxy]-1,4-diaza-spiro[5.5]undecane-5-one dimaleate, use thereof as a medicament and method for the production thereof | |
TWI230156B (en) | Quinazoline compounds with inhibitory activity on signal transduction mediated by tyrosine kinases, pharmaceutical compositions containing these compounds and their use | |
TW202136263A (en) | New egfr inhibitors | |
NZ620263B2 (en) | 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor |